Podcasts about Massachusetts General Hospital

Dr. Carole Keim talks with Dr. Victoria Martin, MD, MPH, a gastroenterologist, a specialist who focuses on everything related to the stomach and intestines in babies. Dr. Martin trained in pediatrics and became interested in what happens in baby intestines, especially early on, during training. She talks with Dr. Keim about things like blood in a baby's stool, protein allergies, signs of food allergies in children, and what to look for at home for signs of intestinal distress. She differentiates between what might be cause for concern versus what is normal for infants regarding reflux, breastfeeding, constipation, and more.Dr. Martin explains normal reflux in babies and what to try at home before getting to a doctor's appointment in regards to concerns about too much spitting up. She and Dr. Keim discuss food allergies in infants, common concerns over what allergens are transferred from a mother's breastmilk, and why there are things to consider before immediately eliminating foods from a mother's diet if an allergy is suspected. Food allergies, causes, and substitute formulas are discussed, and Dr. Martin shares insights into possibilities for preventing the development of allergies, when to introduce solid foods, and what a baby's poop reveals about the baby's health. It's an episode full of practical advice and in-depth knowledge from Dr. Martin about babies' intestinal functions.    About Dr. Victoria Martin, MD, MPH:Dr. Martin graduated from Harvard University with a degree in Biology. She completed her medical school and residency training in Pediatrics at the University of Massachusetts Medical School. She then completed her fellowship training at the Massachusetts General Hospital for Children in the division of Pediatric Gastroenterology and Nutrition, during which she was awarded the Outstanding Teaching Award by the pediatric housestaff. She also completed a Master's degree in Public Health in Clinical Effectiveness at the Harvard School of Public Health.Dr. Martin's clinical and research interests include the developing infant microbiome and its potential role in gastrointestinal food allergic diseases, including allergic proctocolitis and eosinophilic esophagitis.__ Resources discussed in this episode:The Holistic Mamas Handbook is available on AmazonThe Baby Manual is also available on Amazon__Contact Dr. Carole Keim MDLinktree: linktr.ee/drkeimTiktok: @dr.keimInstagram: @doctoratyourdoor Contact Dr. Victoria Martin, MD, MPHWorkplace: Mass General Brigham for ChildrenLinkedIn: Victoria-Mackenzie-Martin-644337102

We have published 120 episodes since 2019. For this new season, we thought it would be a good idea to look back on some of the highlights of our conversations and select 20 episodes that resonated with veterans, service members, military families, and the civilians who support them.But first up, you'll hear from some of the folks at Home Base who wake up every day with the same mission in mind, no matter what they do at the Center of Excellence in the Navy Yard and beyond. For this episode, you will hear a brief conversation with the Admissions Coordinator at Home Base, Zachary Morin. Born and raised in Massachusetts, Zach spent two years serving with AmeriCorps in the Miami-Dade Public Schools, working with middle school students on literacy, social and emotional development, as well as civic engagement. Upon completing his service, Zachary returned to New England to lead the College Ready Communities program in Northern Rhode Island. Here, his work included holistic programming for vulnerable youth populations and overall community engagement initiatives. He also has a creative/performative side, which he will talk about.Following my conversation with Zach, you'll hear an episode from 2023 with the Pulitzer Prize and Emmy-winning cartoonist, Garry Trudeau. Garry is also an Army Commander's Award for Public Service honoree. In this conversation, Garry tells us that not only did his dad and grandfather both serve, but they were also both physicians. He recounts an eye-opening visit to Walter Reed Medical Center, with stories of injury and resilience that not only informed his storytelling but have had lasting impacts on him. As a big fan of author Sebastian Junger, he discusses the innate need for the tribe to survive, and explains a bit of his creative process. Part Two will come shortly.Run To Home Base: Join Ron and his team and sign up individually or on another team at the 16th annual Run To Home Base on July 26th, 2025, at Fenway Park! Go to runtohomebase.orgPlease visit homebase.org for updates, programming, and resources if you or someone you know is struggling.Home Base Nation is the official podcast for the Home Base Program for Veterans and Military Families. Our team sees veterans, service members, and their families addressing the invisible wounds of war at no cost. This is all made possible thanks to a grateful nation. To learn more about how to help, visit us at www.homebase.org. If you or anyone you know would like to connect to care, you can also reach us at 617-724-5202.Follow Home Base on Twitter, Facebook, Instagram, LinkedInThe Home Base Nation Team is Steve Monaco, Army Veteran Kelly Field, Justin Scheinert, Chuck Clough, with COO Michael Allard, Brigadier General Jack Hammond, and Peter Smyth.Producer and Host: Dr. Ron HirschbergAssistant Producer, Editor: Chuck CloughChairman, Home Base Media Lab: Peter SmythThe views expressed by guests on the Home Base Nation podcast are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent. Views and opinions expressed by guests are those of the guests and do not necessarily reflect the views of the Massachusetts General Hospital, Home Base, the Red Sox Foundation, or any of its officials.

Dr Haley Ellis from Massachusetts General Hospital in Boston, Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora, Dr Sara Lonardi from the Veneto Institute of Oncology IOV-IRCCS in Padua, Italy, and Dr Kanwal Raghav from The University of Texas MD Anderson Cancer Center in Houston discuss patient cases and provide their perspectives on clinical datasets informing the care of patients with HER2-positive gastrointestinal cancer.  CME information and select publications here.

Dr Haley Ellis from Massachusetts General Hospital in Boston, Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora, Dr Sara Lonardi from the Veneto Institute of Oncology IOV-IRCCS in Padua, Italy, and Dr Kanwal Raghav from The University of Texas MD Anderson Cancer Center in Houston discuss patient cases and provide their perspectives on clinical datasets informing the care of patients with HER2-positive gastrointestinal cancer.  CME information and select publications here.

In this powerful episode of Research Renaissance, host Deborah Westphal sits down with Dr. Rachel Buckley, Associate Professor of Neurology at Massachusetts General Hospital and Harvard Medical School. Together, they explore a growing body of research that challenges long-standing assumptions about sex differences in Alzheimer's disease.Dr. Buckley shares her unexpected journey from skepticism to advocacy in studying how biological sex and hormonal changes—particularly around menopause—can influence Alzheimer's risk, pathology, and progression. From PET scans to postmortem tissue studies, she unpacks what we now know about tau pathology in women, the role of hormone therapy, and how reproductive history may shape brain health.You'll also hear about:Why women are disproportionately impacted by Alzheimer's—and why it's more than just longevityHow timing of hormone therapy may impact tau buildupSurprising research around pregnancy, caregiving, and even the X chromosomeWhere the research gaps still exist—and how AI might help close themWhy training the next generation of sex-based neuroscientists is essentialWhether you're a caregiver, clinician, researcher, or simply curious about how brain health intersects with gender, this episode offers eye-opening insight and hope for the future.Guest Bio: Dr. Rachel Buckley is an internationally recognized neuroscientist focused on the intersection of sex differences and Alzheimer's disease. She leads groundbreaking research at Massachusetts General Hospital and serves as Chair of the Alzheimer's Association's Sex and Gender Professional Interest Area.Resources & Links: 

Dr Haley Ellis from Massachusetts General Hospital in Boston, Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora, Dr Sara Lonardi from the Veneto Institute of Oncology IOV-IRCCS in Padua, Italy, and Dr Kanwal Raghav from The University of Texas MD Anderson Cancer Center in Houston discuss patient cases and provide their perspectives on clinical datasets informing the care of patients with HER2-positive gastrointestinal cancer.  CME information and select publications here.

Drs. Hope Rugo, Sheri Brenner, and Mikolaj Slawkowski-Rode discuss the struggle that health care professionals experience when terminally ill patients are suffering and approaches to help clinicians understand and respond to suffering in a more patient-centered and therapeutic way. TRANSCRIPT Dr. Hope Rugo: Hello, and welcome to By the Book, a monthly podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book.  I'm your host, Dr. Hope Rugo. I'm director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center, and I'm also the editor-in-chief of the Educational Book. On today's episode, we'll be exploring the complexities of grief and oncology and the struggle we experience as healthcare professionals when terminally ill patients are suffering. Our guests will discuss approaches to help clinicians understand and respond to suffering in a more patient-centered and therapeutic way, as outlined in their recently published article titled, “Oncology and Suffering: Strategies on Coping With Grief for Healthcare Professionals.” I'm delighted today to welcome Dr. Keri Brenner, a clinical associate professor of medicine, palliative care attending, and psychiatrist at Stanford University, and Dr. Mikołaj Sławkowski-Rode, a senior research fellow in philosophy in the Humanities Research Institute at the University of Buckingham, where he also serves as director of graduate research in p hilosophy. He is also a research fellow in philosophy at Blackfriars Hall at the University of Oxford and associate professor at the University of Warsaw.  Our full disclosures are available in the transcript of this episode. Dr. Brenner and Dr. Sławkowski-Rode, thanks for being on the podcast today. Dr. Keri Brenner: Great to be here, Dr. Rugo. Thank you so much for that kind introduction. Dr. Mikołaj Sławkowski-Rode: Thank you very much, Dr. Rugo. It's a pleasure and an honor. Dr. Hope Rugo: So I'm going to start with some questions for both of you. I'll start with Dr. Brenner. You've spoken and written about the concept of suffering when there is no cure. For oncologists, what does it mean to attune to suffering, not just disease? And how might this impact the way they show up in difficult conversations with patients? Dr. Keri Brenner: Suffering is something that's so omnipresent in the work of clinical oncology, and I like to begin by just thinking about what is suffering, because it's a word that we use so commonly, and yet, it's important to know what we're talking about. I think about the definition of Eric Cassell, who was a beloved mentor of mine for decades, and he defined suffering as the state of severe distress that's associated with events that threaten the intactness of a person. And my colleague here at Stanford, Tyler Tate, has been working on a definition of suffering that encompasses the experience of a gap between how things are versus how things ought to be. Both of these definitions really touch upon suffering in a person-centered way that's relational about one's identity, meaning, autonomy, and connectedness with others. So these definitions alone remind us that suffering calls for a person-centered response, not the patient as a pathology, but the panoramic view of who the patient is as a person and their lived reality of illness. And in this light, the therapeutic alliance becomes one of our most active ingredients in care. The therapeutic alliance is that collaborative, trusting bond as persons that we have between clinician and patient, and it's actually one of the most powerful predictors of meaningful outcomes in our care, especially in oncologic care.  You know, I'll never forget my first day of internship at Massachusetts General Hospital. A faculty lecturer shared this really sage insight with us that left this indelible mark. She shared, “As physicians and healers, your very self is the primary instrument of healing. Our being is the median of the medicine.” So, our very selves as embodied, relationally grounded people, that's the median of the medicine and the first most enduring medicine that we offer. That has really borne fruit in the evidence that we see around the therapeutic alliance. And we see this in oncologic care, that in advanced cancer, a strong alliance with one's oncologist truly improves a patient's quality of life, treatment adherence, emotional well-being, and even surpasses structured interventions like psychotherapeutic interventions. Dr. Hope Rugo: That's just incredibly helpful information and actually terminology as well, and I think the concept of suffering differs so much. Suffering comes in many shapes and forms, and I think you really have highlighted that. But many oncologists struggle with knowing what to do when patients are suffering but can't be fixed, and I think a lot of times that has to do with oncologists when patients have pain or shortness of breath or issues like that. There are obviously many ways people suffer. But I think what's really challenging is how clinicians understand suffering and what the best approaches to respond to suffering are in the best patient-centered and therapeutic way. Dr. Keri Brenner: I get that question a lot from my trainees in palliative care, not knowing what to do. And my first response is, this is about how to be, not about knowing what to do, but how to be. In our medical training, we're trained often how to think and treat, but rarely how to be, how to accompany others. And I often have this image that I tell my trainees of, instead of this hierarchical approach of a fix-it mentality of all we're going to do, when it comes to elements of unavoidable loss, mortality, unavoidable sufferings, I imagine something more like accompaniment, a patient walking through some dark caverns, and I am accompanying them, trying to walk beside them, shining a light as a guide throughout that darkness. So it's a spirit of being and walking with. And it's so tempting in medicine to either avoid the suffering altogether or potentially overidentify with it, where the suffering just becomes so all-consuming like it's our own. And we're taught to instead strike a balance of authentic accompaniment through it. I often teach this key concept in my palli-psych work with my team about formulation. Formulation is a working hypothesis. It's taking a step back and asking, “Why? Why is this patient behaving in this manner? What might the patient's core inner struggle be?” Because asking that “why” and understanding the nuanced dimensions of a patient's core inner struggle will really help guide our therapeutic interactions and guide the way that we accompany them and where we choose to shine that light as we're walking with them. And oftentimes people think, “Well Keri, that sounds so sappy or oversentimental,” and it's not. You know, I'm just thinking about a case that I had a couple months ago, and it was a 28-year-old man with gastric cancer, metastatic disease, and that 28-year-old man, he was actually a college Division I athlete, and his dad was an acclaimed Division I coach. And our typical open-ended palliative care questions, that approach, infuriated them. They needed to know that I was showing up confident, competent, and that I was ready, on my A-game, with a real plan for them to follow through. And so my formulation about them was they needed somebody to show up with that confidence and competence, like the Division I athletes that they were, to really meet them and accompany them where they were on how they were going to walk through that experience of illness. Dr. Hope Rugo: These kinds of insights are so helpful to think about how we manage something that we face every day in oncology care. And I think that there are many ways to manage this.  Maybe I'll ask Dr. Sławkowski-Rode one question just that I think sequences nicely with what you're talking about.  A lot of our patients are trying to think about sort of the bigger picture and how that might help clinicians understand and support patients. So, the whole concept of spirituality, you know, how can we really use that as oncology clinicians to better understand and support patients with advanced illness, and how can that help patients themselves? And we'll talk about that in two different ways, but we'll just start with this broader question. Dr. Mikołaj Sławkowski-Rode: I think spirituality, and here, I usually refer to spirituality in terms of religious belief. Most people in the world are religious believers, and it is very intuitive and natural that religious beliefs would be a resource that people who help patients with a terminal diagnosis and healthcare professionals who work with those patients appeal to when they try to help them deal with the trauma and the stress of these situations.  Now, I think that the interesting thing there is that very often the benefit of appealing to a religious belief is misunderstood in terms of what it delivers. And there are many, many studies on how religious belief can be used to support therapy and to support patients in getting through the experience of suffering and defeating cancer or facing a terminal diagnosis. There's a wealth of literature on this. But most of the literature focuses on this idea that by appealing to religious belief, we help patients and healthcare practitioners who are working with them get over the fact and that there's a terminal diagnosis determining the course of someone's life and get on with our lives and engaging with whatever other pursuits we might have, with our job if we're healthcare practitioners, and with the other things that we might be passionate about in our lives. And the idea here is that this is what religion allows us to do because we sort of defer the need to worry about what's going to happen to us until the afterlife or some perspective beyond the horizon of our life here.  However, my view is – I have worked beyond philosophy also with theologians from many traditions, and my view here is that religion is something that does allow us to get on with our life but not because we're able to move on or move past the concerns that are being threatened by illness or death, but by forming stronger bonds with these things that we value in our life in a way and to have a sense of hope that these will be things that we will be able to keep an attachment to despite the threat to our life. So, in a sense, I think very many approaches in the field have the benefit of religion upside down, as it were, when it comes to helping patients and healthcare professionals who are engaged with their illness and treating it. Dr. Hope Rugo: You know, it's really interesting the points that you make, and I think really important, but, you know, sometimes the oncologists are really struggling with their own emotional reactions, how they are reacting to patients, and dealing with sort of taking on the burden, which, Dr. Brenner, you were mentioning earlier. How can oncologists be aware of their own emotional reactions? You know, they're struggling with this patient who they're very attached to who's dying or whatever the situation is, but you want to avoid burnout as an oncologist but also understand the patient's inner world and support them. Dr. Keri Brenner: I believe that these affective, emotional states, they're contagious. As we accompany patients through these tragic losses, it's very normal and expected that we ourselves will experience that full range of the human experience as we accompany the patients. And so the more that we can recognize that this is a normative dimension of our work, to have a nonjudgmental stance about the whole panoramic set of emotions that we'll experience as we accompany patients with curiosity and openness about that, the more sustainable the work will become. And I often think about the concept of countertransference given to us by Sigmund Freud over 100 years ago. Countertransference is the clinician's response to the patient, the thoughts, feelings, associations that come up within us, shaped by our own history, our own life events, those unconscious processes that come to the foreground as we are accompanying patients with illness. And that is a natural part of the human experience. Historically, countertransference was viewed as something negative, and now it's actually seen as a key that can unlock and enlighten the formulation about what might be going on within the patient themselves even. You know, I was with a patient a couple weeks ago, and I found myself feeling pretty helpless and hopeless in the encounter as I was trying to care for them. And I recognized that countertransference within myself that I was feeling demoralized. It was a prompt for me to take a step back, get on the balcony, and be curious about that because I normally don't feel helpless and hopeless caring for my patients. Well, ultimately, I discovered through processing it with my interdisciplinary team that the patient likely had demoralization as a clinical syndrome, and so it's natural many of us were feeling helpless and hopeless also accompanying them with their care. And it allowed us to have a greater interdisciplinary approach and a more therapeutic response and deeper empathy for the patient's plight. And we can really be curious about our countertransferences. You know, a few months ago, I was feeling bored and distracted in a family meeting, which is quite atypical for me when I'm sharing serious illness news. And it was actually a key that allowed me to recognize that the patient was trying to distract all of us talking about inconsequential facts and details rather than the gravitas of her illness.  Being curious about these affective states really allows us to have greater sustainability within our own practice because it normalizes that human spectrum of emotions and also allows us to reduce unconscious bias and have greater inclusivity with our practice because what Freud also said is that what we can't recognize and say within our own selves, if we don't have that self-reflective capacity, it will come out in what we do. So really recognizing and having the self-awareness and naming some of these emotions with trusted colleagues or even within our own selves allows us to ensure that it doesn't come out in aberrant behaviors like avoiding the patient, staving off that patient till the end of the day, or overtreating, offering more chemotherapy or not having the goals of care, doing everything possible when we know that that might result in medically ineffective care. Dr. Hope Rugo: Yeah, I love the comments that you made, sort of weaving in Freud, but also, I think the importance of talking to colleagues and to sharing some of these issues because I do think that oncologists suffer from the fact that no one else in your life wants to hear about dying people. They don't really want to hear about the tragic cases either. So, I think that using your community, your oncology community and greater community within medicine, is an important part of being able to sort of process. Dr. Keri Brenner: Yes, and Dr. Rugo, this came up in our ASCO [Education] Session. I'd love to double click into some of those ways that we can do this that aren't too time consuming in our everyday practice. You know, within palliative care, we have interdisciplinary rounds where we process complex cases. Some of us do case supervision with a trusted mentor or colleague where we bring complex cases to them. My team and I offer process rounds virtually where we go through countertransference, formulation, and therapeutic responses on some tough cases.  You know, on a personal note, just last week when I left a family meeting feeling really depleted and stuck, I called one of my trusted colleagues and just for 3 minutes constructively, sort of cathartically vented what was coming up within me after that family meeting, which allowed me to have more of an enlightened stance on what to do next and how to be therapeutically helpful for the case. One of my colleagues calls this "friend-tors." They coined the phrase, and they actually wrote a paper about it. Who within your peer group of trusted colleagues can you utilize and phone in real time or have process opportunities with to get a pulse check on where what's coming up within us as we're doing this work? Dr. Hope Rugo: Yeah, and it's an interesting question about how one does that and, you know, maintaining that as you move institutions or change places or become more senior, it's really important.  One of the, I think, the challenges sometimes is that we come from different places from our patients, and that can be an issue, I think when our patients are very religious and the provider is not, or the reverse, patients who don't have religious beliefs and you're trying to sort of focus on the spirituality, but it doesn't really ring true. So, Dr. Sławkowski-Rode, what resources can patients and practitioners draw on when they're facing death and loss in the absence of, or just different religious beliefs that don't fit into the standard model? Dr. Mikołaj Sławkowski-Rode: You're absolutely right that this can be an extremely problematic situation to be in when there is that disconnect of religious belief or more generally spiritual engagement with the situation that we're in. But I just wanted to tie into what Dr. Brenner was saying just before. I couldn't agree more, and I think that a lot of healthcare practitioners, oncologists in particular who I've had the pleasure to talk to at ASCO and at other events as well, are very often quite skeptical about emotional engagement in their profession. They feel as though this is something to be managed, as it were, and something that gets in the way. And they can often be very critical of methods that help them understand the emotions and extend them towards patients because they feel that this will be an obstacle to doing their job and potentially an obstacle also to helping patients to their full ability if they focus on their own emotions or the burden that emotionally, spiritually, and in other ways the illness is for the patient. They feel that they should be focusing on the cancer rather than on the patient's emotions. And I think that a useful comparison, although, you know, perhaps slightly drastic, is that of combat experience of soldiers. They also need to be up and running and can't be too emotionally invested in the situation that they're in. But there's a crucial difference, which is that soldiers are usually engaged in very short bursts of activity with the time to go back and rethink, and they often have a lot of support for this in between. Whereas doctors are in a profession where their exposure to the emotions of patients and their own emotions, the emotions of families of patients is constant. And I think that there's a great danger in thinking that this is something to be avoided and something to compartmentalize in order to avoid burnout. I think, in a way, burnout is more sure to happen if your emotions and your attachment to your patients goes ignored for too long. So that's just following up on Keri's absolutely excellent points. As far as the disconnect is concerned, that's, in fact, an area in which I'm particularly interested in. That's where my research comes in. I'm interested in the kinds of connections that we have with other people, especially in terms of maintaining bonds when there is no spiritual belief, no spiritual backdrop to support this connection. In most religious traditions, we have the framework of the religious belief that tells us that the person who we've lost or the values that have become undermined in our life are something that hasn't been destroyed permanently but something that we can still believe we have a deep connection to despite its absence from our life. And how do you rebuild that sense of the existence of the things that you have perceivably lost without the appeal to some sort of transcendent realm which is defined by a given religion? And that is a hard question. That's a question, I think, that can be answered partly by psychology but also partly by philosophy in terms of looking at who we are as human beings and our nature as people who are essentially, or as entities that are essentially connected to one another. That connection, I believe, is more direct than the mediation of religion might at first suggest. I think that we essentially share the world not only physically, it's not just the case that we're all here, but more importantly, the world that we live in is not just the physical world but the world of meanings and values that helps us orient ourselves in society and amongst one another as friends and foes. And it is that shared sense of the world that we can appeal to when we're thinking about retaining the value or retaining the connection with the people who we have lost or the people who are helping through, go through an experience of facing death. And just to finish, there's a very interesting question, I think, something that we possibly don't have time to explore, about the degree of connection that we have with other people. So, what I've just been saying is something that rings more true or is more intuitive when we think about the connections that we have to our closest ones. We share a similar outlook onto the world, and our preferences and our moods and our emotions and our values are shaped by life with the other person. And so, appealing to these values can give us a sense of a continued presence. But what in those relationships where the connection isn't that close? For example, given the topic of this podcast, the connection that a patient has with their doctor and vice versa. In what sense can we talk about a shared world of experience? Well, I think, obviously, we should admit degrees to the kind of relationship that can sustain our connection with another person. But at the same time, I don't think there's a clear cutoff point. And I think part of emotional engagement in medical practice is finding yourself somewhere on that spectrum rather than thinking you're completely off of it. That's what I would say. Dr. Hope Rugo: That's very helpful and I think a very helpful way of thinking about how to manage this challenging situation for all of us.  One of the things that really, I think, is a big question for all of us throughout our careers, is when to address the dying process and how to do that. Dr. Brenner, you know, I still struggle with this – what to do when patients refuse to discuss end-of-life but they're very close to end of life? They don't want to talk about it. It's very stressful for all of us, even where you're going to be, how you're going to manage this. They're just absolutely opposed to that discussion. How should we approach those kinds of discussions? How do we manage that? How do you address the code discussion, which is so important? You know, these patients are not able to stay at home at end-of-life in general, so you really do need to have a code discussion before you're admitting them. It actually ends up being kind of a challenge and a mess all around. You know, I would love your advice about how to manage those situations. Dr. Keri Brenner: I think that's one of the most piercing and relevant inquiries we have within our clinical work and challenges. I often think of denial not as an all-or-nothing concept but rather as parts of self. There's a part of everyone's being where the unconscious believes it's immortal and will live on forever, and yet we all know intellectually that we all have mortality and finitude and transience, and that time will end. We often think of this work as more iterative and gradual and exposure based. There's potency to words. Saying, “You are dying within days,” is a lot higher potency of a phrase to share than, “This is serious illness. This illness is incurable. Time might be shorter than we hoped.” And so the earlier and more upstream we begin to have these conversations, even in small, subtle ways, it starts to begin to expose the patient to the concept so they can go from the head to the heart, not only knowing their prognosis intellectually but also affectively, to integrate it into who they are as a person because all patients are trying to live well while also we're gradually exposing them to this awareness of mortality within their own lived experience of illness. And that, ideally, happens gradually over time. Now, there are moments where the medical frame is very limited, and we might have short days, and we have to uptitrate those words and really accompany them more radically through those high-affective moments. And that's when we have to take a lot of more nuanced approaches, but I would say the more earlier and upstream the better. And then the second piece to that question as well is coping with our own mortality. The more we can be comfortable with our own transience and finitude and limitations, the more we will be able to accompany others through that. And even within my own life, I've had to integrate losses in a way where before I go in to talk to one of my own palliative care patients, one mantra I often say to myself is, “I'm just a few steps behind you. I don't know if it's going to be 30 days or 30 years, but I'm just a few steps behind you on this finite, transient road of life that is the human experience.” And that creates a stance of accompaniment that patients really can experience as they're traversing these tragedies. Dr. Hope Rugo: That's great. And I think those are really important points and actually some pearls, which I think we can take into the clinic. I think being really concrete when really the expected life expectancy is a few days to a couple of weeks can be very, very helpful. And making sure the patients hear you, but also continuing to let them know that, as oncologists, we're here for them. We're not abandoning them. I think that's a big worry for many, certainly of my patients, is that somehow when they would go to hospice or be a ‘no code', that we're not going to support them anymore or treat them anymore. That is a really important process of that as well. And of course, engaging the team makes a big difference because the whole oncology team can help to manage situations that are particularly challenging like that. And just as we close, I wanted to ask one last question of you, Dr. Brenner, that suffering, grief, and burnout, you've really made the point that these are not problems to fix but dimensions that we want to attend to and acknowledge as part of our lives, the dying process is part of all of our lives. It's just dealing with this in the unexpected and the, I think, unpredictability of life, you know, that people take on a lot of guilt and all sorts of things about, all sorts of emotions. And the question is now, people have listened to this podcast, what can they take back to their oncology teams to build a culture that supports clinicians and their team at large to engage with these realities in a meaningful and sustainable way? I really feel like if we could build the whole team approach where we're supporting each other and supporting the patients together, that that will help this process immeasurably. Dr. Keri Brenner: Yes, and I'm thinking about Dr. Sławkowski-Rode's observation about the combat analogy, and it made me recognize this distinction between suppression and repression. Repression is this unconscious process, and this is what we're taught to do in medical training all the time, to just involuntarily shove that tragedy under the rug, just forget about it and see the next patient and move on. And we know that if we keep unconsciously shoving things under the rug, that it will lead to burnout and lack of sustainability for our clinical teams. Suppression is a more conscious process. That deliberate effort to say, “This was a tragedy that I bore witness to. I know I need to put that in a box on the shelf for now because I have 10 other patients I have to see.” And yet, do I work in a culture where I can take that off the shelf during particular moments and process it with my interdisciplinary team, phone a friend, talk to a trusted colleague, have some trusted case supervision around it, or process rounds around it, talk to my social worker? And I think the more that we model this type of self-reflective capacity as attendings, folks who have been in the field for decades, the more we create that ethos and culture that is sustainable because clinician self-reflection is never a weakness, rather it's a silent strength. Clinician self-reflection is this portal for wisdom, connectedness, sustainability, and ultimately transformative growth within ourselves. Dr. Hope Rugo: That's such a great point, and I think this whole discussion has been so helpful for me and I hope for our audience that we really can take these points and bring them to our practice. I think, “Wow, this is such a great conversation. I'd like to have the team as a whole listen to this as ways to sort of strategize talking about the process, our patients, and being supportive as a team, understanding how we manage spirituality when it connects and when it doesn't.” All of these points, they're bringing in how we process these issues and the whole idea of suppressing versus sort of deciding that it never happened at all is, I think, very important because that's just a tool for managing our daily lives, our busy clinics, and everything we manage. Dr. Keri Brenner: And Dr. Rugo, it's reminding me at Stanford, you know, we have this weekly practice that's just a ritual where every Friday morning for 30 minutes, our social worker leads a process rounds with us as a team, where we talk about how the work that we're doing clinically is affecting us in our lives in ways that have joy and greater meaning and connectedness and other ways that might be depleting. And that kind of authentic vulnerability with one another allows us to show up more authentically for our patients. So those rituals, that small 30 minutes once a week, goes a long way. And it reminds me that sometimes slowing things down with those rituals can really get us to more meaningful, transformative places ultimately. Dr. Hope Rugo: It's a great idea, and I think, you know, making time for that in everybody's busy days where they just don't have any time anymore is important. And you don't have to do it weekly, you could even do something monthly. I think there's a lot of options, and that's a great suggestion. I want to thank you both for taking your time out for this enriching and incredibly helpful conversation. Our listeners will find a link to the Ed Book article we discussed today, which is excellent, in the transcript of this episode. I want to thank you again, Dr. Brenner and Dr. Sławkowski-Rode, for your time and for your excellent thoughts and advice and direction. Dr. Mikołaj Sławkowski-Rode: Thank you very much, Dr. Rugo. Dr. Keri Brenner: Thank you. Dr. Hope Rugo: And thanks to our listeners for joining us today. Please join us again next month on By the Book for more insightful views on topics you'll be hearing at the education sessions from ASCO meetings and our deep dives on new approaches that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:      Dr. Hope Rugo @hope.rugo Dr. Keri Brenner @keri_brenner Dr. Mikolaj Slawkowski-Rode @MikolajRode Follow ASCO on social media:      @ASCO on X (formerly Twitter)      ASCO on Bluesky     ASCO on Facebook      ASCO on LinkedIn      Disclosures:     Dr. Hope Rugo: Honoraria: Mylan/Viatris, Chugai Pharma Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx Dr. Keri Brenner: No relationships to disclose Dr. Mikolaj Slawkowski-Rode: No relationships to disclose    

Dr Jeremy Abramson from Massachusetts General Hospital in Boston, Dr Joshua Brody from the Tisch Cancer Institute in New York, New York, Dr Christopher Flowers from The University of Texas MD Anderson Cancer Center in Houston, Dr Ann LaCasce from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Tycel Phillips from City of Hope Comprehensive Cancer Center in Duarte, California, discuss patient cases and provide their perspectives on clinical datasets informing the care of patients with non-Hodgkin lymphoma. CME information and select publications here.

In this episode of SurgOnc Today, Dr. Katherine Poruk from Mayo Clinic Florida and Dr. Erika Rangel of Massachusetts General Hospital discuss fertility and family planning for surgeons. Together, they explore how surgical culture impacts childbearing decisions, the risks of infertility and pregnancy complications, and the systemic changes needed to support surgeons with or without children.

We have published 120 episodes since 2019. For this new season, we thought it would be a good idea to look back on some of the highlights of our conversations and select 20 episodes that resonated with veterans, service members, military families, and the civilians who support them.But first up, you'll hear from some of the folks at Home Base who wake up every day with the same mission in mind, no matter what they do at the Center of Excellence in the Navy Yard and beyond. If you are just tuning in to the show, our host, Dr. Ron Hirschberg, and I have reviewed more than 120 published episodes since 2019. We chose 20 or so to share with you again that resonated with veterans, service members, military families, and the civilians who support them.For this episode, you will hear a brief conversation with Dr. Drew Teer who completed his PhD in clinical psychology from Emory University, where he also finished his internship at Emory University's School of Medicine at Grady Memorial Hospital as well as his postdoctoral fellowship with the Emory Healthcare Veterans Program – one of the other Warrior Care Network sites. Drew is passionate about providing science-based treatments for PTSD and other internalizing disorders. His research interests include identifying factors that may influence responses to PTSD treatment and enhancing treatments for underserved and complex trauma populations.Following my conversation with Dr. Teer, you'll hear an episode with 7-time nominated and 2-time Grammy winner and Marine Veteran, Shaggy. For Shaggy, music has been a vehicle to bring different kinds of people together for a shared experience. But it's not just the music that does this; it's his spirit and grit, which were undoubtedly shaped by his Marine background.Run To Home Base: Join Ron and his team and sign up individually or on another team at the 16th annual Run To Home Base on July 26th, 2025, at Fenway Park! Go to runtohomebase.orgPlease visit homebase.org for updates, programming, and resources if you or someone you know is struggling.Home Base Nation is the official podcast for the Home Base Program for Veterans and Military Families. Our team sees veterans, service members, and their families addressing the invisible wounds of war at no cost. This is all made possible thanks to a grateful nation. To learn more about how to help, visit us at www.homebase.org. If you or anyone you know would like to connect to care, you can also reach us at 617-724-5202.Follow Home Base on Twitter, Facebook, Instagram, LinkedInThe Home Base Nation Team is Steve Monaco, Army Veteran Kelly Field, Justin Scheinert, Chuck Clough, with COO Michael Allard, Brigadier General Jack Hammond, and Peter Smyth.Producer and Host: Dr. Ron HirschbergAssistant Producer, Editor: Chuck CloughChairman, Home Base Media Lab: Peter SmythThe views expressed by guests on the Home Base Nation podcast are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent. Views and opinions expressed by guests are those of the guests and do not necessarily reflect the views of the Massachusetts General Hospital, Home Base, the Red Sox Foundation, or any of its officials.

Dean's Chat hosts, Drs. Jensen and Richey, welcome Dr. Adam Landsman to Dean's Chat! Adam Landsman, DPM, PhD, FACFAS is an Assistant Professor of Orthopedic Surgery at the Harvard University School of Medicine, and Lead Podiatrist in the Department of Orthopedics at the Massachusetts General Hospital in Boston.  Dr. Landsman is Board Certified in Foot Surgery by the American Board of Foot and Ankle Surgery. He holds a PhD in Bioengineering in addition to his Podiatric Medicine Degree.  Dr. Landsman has completed over 30 clinical trials, holds 2 patents, and has published 90+ peer-reviewed studies and numerous book chapters. Previously, he served as the Director of Podiatric Research at the Scholl College of Podiatric Medicine, and at Samuel Merritt University. He has lectured extensively in the United States and internationally and has held faculty appointments at Northwestern University, University of Miami, and Harvard University. Enjoy this wonderful, entertaining discussion on paving new paths, inventing new products, and paving the way in research for future generations of podiatrists!

Send us a textJosh Haimson is Co-Founder and CEO of Inductive Bio ( https://www.inductive.bio/about ), a technology company focused on democratizing artificial intelligence (AI) models to transform small molecule drug discovery, eliminating Absorption, Distribution, Metabolism, Excretion and Toxicology (ADMET) bottlenecks with state-of-the-art AI models and generative chemistry, powered by a unique pre-competitive data consortium.Josh has spent his career focused on the intersection of machine learning, product, and life sciences/healthcare.Prior to Inductive, Josh was the Director of Product for the ML and data curation organizations at Flatiron Health, where his teams worked to generate real-world evidence (RWE) at scale across Flatiron's network of over 2 million active cancer patients for use by researchers in pharma, academia, and government.Prior to Flatiron, Josh was at MIT studying computer science and working with researchers at Massachusetts General Hospital to use ML and NLP to predict patient response to cardiac resynchronization therapy.#JoshHaimson #InductiveBio #SmallMolecule #DrugDiscovery #Absorption #Distribution #Metabolism #Excretion #Toxicology #ADMET #AI #GenerativeChemistry #MachineLearning #CardiacResynchronizationTherapy #MolecularGlue #FlatironHealth #PreCompetitiveDataConsortium #RealWorldEvidence #RealWorldData #RWE #ArtificialIntelligence  #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

In the corner of the ICU, on multiple pressors, distended, oliguric, and intubated you'll find the necrotizing pancreatitis patient. Sounds intimidating, but with the persistence, patience, and the proper care these patients can make it! In this episode from the HPB team at Behind the Knife listen in as we discuss the Step-Up approach, when to surgically intervene, various approaches to pancreatic Necrosectomy, and additional aspects of the multidisciplinary care required for the successful treatment of necrotizing pancreatitis.  Hosts Anish J. Jain MD (@anishjayjain) is a current PGY3 General Surgery Resident at Stanford University and a former T32 Research Fellow at the University of Texas MD Anderson Cancer Center. Jon M. Harrison is a 2nd year HPB Surgery Fellow at Stanford University. He will be joining as faculty at the Massachusetts General Hospital in Boston, MA at the conclusion of his fellowship in July 2024.    Learning Objectives ·      Develop an understanding of the severity of necrotizing pancreatitis and the proper indications to surgical intervene on this often-tenuous patients.  ·      Develop an understanding of the Step-Up approach and key aspects (reimaging, clinical status, physiologic status, etc.) that determine when to “step-up” treatment for patients with necrotizing pancreatitis. ·      Develop an understanding of long term sequalae and complications associated with necrotizing pancreatitis and operative management ·      Develop an understanding of multidisciplinary care and long-term follow-up necessary for adequate treatment of patients suffering from necrotizing pancreatitis. Suggested Reading Maurer LR, Fagenholz PJ. Contemporary Surgical Management of Pancreatic Necrosis. JAMA Surg. 2023;158(1):81–88. doi:10.1001/jamasurg.2022.5695 https://pubmed.ncbi.nlm.nih.gov/36383374/ Harrison JM, Day H, Arnow K, Ngongoni RF, Joseph A, Aldridge T, Wheeler KJ, DeLong JC, Bergquist JR, Worth PJ, Dua MM, Friedland S, Park W, Eldika S, Hwang JH, Visser BC. What's Behind it all: A Retrospective Cohort Study of Retrogastric Pancreatic Necrosis Management. Ann Surg. 2024 Sep 3. doi: 10.1097/SLA.0000000000006521. https://pubmed.ncbi.nlm.nih.gov/39225420/ Harrison JM, Visser BC. Not Dead Yet: Managing the Abdominal Catastrophe in Necrotizing Pancreatitis. Pancreas. 2025 May 20. doi: 10.1097/MPA.0000000000002512. https://pubmed.ncbi.nlm.nih.gov/40388698/ Harrison JM, Li AY, Sceats LA, Bergquist JR, Dua MM, Visser BC. Two-Port Minimally Invasive Nephrolaparoscopic Retroperitoneal Debridement for Pancreatic Necrosis. J Am Coll Surg. 2024 Dec 1;239(6):e7-e12. doi: 10.1097/XCS.0000000000001152. https://pubmed.ncbi.nlm.nih.gov/39051721/ van Santvoort HC, Besselink MG, Bakker OJ, Hofker HS, Boermeester MA, Dejong CH, van Goor H, Schaapherder AF, van Eijck CH, Bollen TL, van Ramshorst B, Nieuwenhuijs VB, Timmer R, Laméris JS, Kruyt PM, Manusama ER, van der Harst E, van der Schelling GP, Karsten T, Hesselink EJ, van Laarhoven CJ, Rosman C, Bosscha K, de Wit RJ, Houdijk AP, van Leeuwen MS, Buskens E, Gooszen HG; Dutch Pancreatitis Study Group. A step-up approach or open necrosectomy for necrotizing pancreatitis. N Engl J Med. 2010 Apr 22;362(16):1491-502. doi: 10.1056/NEJMoa0908821. https://pubmed.ncbi.nlm.nih.gov/20410514/ Bang JY, Arnoletti JP, Holt BA, Sutton B, Hasan MK, Navaneethan U, Feranec N, Wilcox CM, Tharian B, Hawes RH, Varadarajulu S. An Endoscopic Transluminal Approach, Compared With Minimally Invasive Surgery, Reduces Complications and Costs for Patients With Necrotizing Pancreatitis. Gastroenterology. 2019 Mar;156(4):1027-1040.e3. doi: 10.1053/j.gastro.2018.11.031. https://pubmed.ncbi.nlm.nih.gov/30452918/ Zyromski NJ, Nakeeb A, House MG, Jester AL. Transgastric Pancreatic Necrosectomy: How I Do It. J Gastrointest Surg. 2016 Feb;20(2):445-9. doi: 10.1007/s11605-015-3058-y. https://pubmed.ncbi.nlm.nih.gov/26691148/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

  In this Rheumatology Rafael Medina Subspecialty episode, Dr. Ana Valle presents a case of Joint pain and skin rash to Dr. Eli Miloslavsky.  Session facilitator: Rahul Pottabathini Case Discussant: Dr. Eli Miloslavsky is a rheumatologist and Associate Professor of Medicine at the Massachusetts General Hospital and Harvard Medical School. Dr. Eli’s Career has been… Read More »Episode 405- Rafael Medina Subspecialty Episode- Joint pain, rash and dry mouth

The goal of this mini series is to spark conversations of these new tools and practices within the community of current and future medical practitioners and staff. It is important for medical professionals to have a say in how these Al tools impact practice to ensure practical and ethical use. Join us in discussions of the history of Al, machine and deep learning. computer visions, natural language processing, responsible Al, and so much more. Let's take a step into the future together.Joining us is Jonathan Theros, Co-Founder and CEO of Dendritic Health AI. A recent MD/MBA graduate from Northwestern University and incoming internal medicine resident at Massachusetts General Hospital, Jon founded his company to address gaps in medical education by developing AI tools that help medical students learn more effectively and prepare for clinical practice. In our conversation, we discussed the future of AI in medical education, the specific tools his startup is building, and how physician entrepreneurs can amplify their impact by supporting the next generation of medical professionals.Dendritic Health AI and Neural Consult:https://www.dendritichealth.comhttps://www.neuralconsult.comEpisode produced by: Caleb Keng & Rohan SethiEpisode recording date: May 15, 2025www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate

Lyme disease was first identified 50 years ago. It has become one of the most recognized and widespread vector-borne illnesses in the world. Transmitted by ticks, this elusive infection presents ongoing challenges in detection and treatment. In this episode, our host Cathy Wurzer and guests Dr. Bobbi Pritt, Microbiology Division Chair at Mayo Clinic; and Dr. Allen Steere, Distinguished Physician at Massachusetts General Hospital delve into how researchers are advancing diagnostic tools to outsmart Lyme disease, and what these innovations mean for the future of global health.Get the latest health information from Mayo Clinic's experts, subscribe to Mayo Clinic's newsletter for free today:  https://mayocl.in/3EcNPNc

In this exciting episode of Research Renaissance, host Deborah Westphal speaks with Dr. Ted Zwang, Assistant Professor of neurology at Massachusetts General Hospital and Harvard Medical School, Dr. Andrew Holbrook, Assistant Professor at UCLA and Jasen Zhang, PhD student in biostatistics in Holbrook's lab. Together, they share how novel neural recording devices and advanced machine learning techniques are transforming the study of Alzheimer's disease.Dr. Ted and Jasen discuss their collaborative project—funded by the Kavli Foundation, Cure Alzheimer's Fund, and the Karen Toffler Charitable Trust—which captures how neurons change over time in Alzheimer's mouse models. They reveal surprising discoveries about how some neurons “go quiet” and later recover—challenging long-held assumptions about neurodegeneration.The conversation also explores how these insights could lead to earlier diagnostics, predictive models of cognitive decline, and more personalized treatments for patients.

In this Editor's Special of The HemOnc Pulse, Blood Cancers Today Managing Editor, Nichole Tucker speaks with Amir Fathi, MD, of Massachusetts General Hospital, about key updates in AML from ASCO 2025. The discussion centers on a phase 2 study of an all-oral regimen—decitabine and cedazuridine plus venetoclax—for patients with newly diagnosed AML who are unfit for intensive induction. Dr. Fathi discusses the potential for these more convenient therapies to shift treatment into the outpatient setting while maintaining effectiveness. He also shares insights on promising triplet regimens incorporating targeted therapies and highlights the need for new strategies for patients with resistant disease subtypes, such as TP53-mutated or venetoclax-refractory AML. Looking ahead, Dr. Fathi previews anticipated data from menin inhibitor trials and the phase 3 Quantum Wild study. This episode is a must-listen for clinicians and researchers interested in the future of AML care.

Pria Anand speaks to managing editor Emily Everett about her story “The Elephant's Child,” which appears in The Common's spring issue. The piece is a vivid retelling of a Hindu myth, the origin story of the elephant-headed god Ganesh. Pria talks about the process of writing and revising many versions of this ancient myth, why she felt inspired by it, and how her literary writing intersects with her career as a neurologist. Pria also discusses her debut book, The Mind Electric: A Neurologist on the Strangeness and Wonder of Our Brains, out this month from Simon & Schuster. The book explores how story and storytelling can illuminate the rich, complex gray areas within the science of the brain, weaving case study, history, fable, and memoir. Pria Anand is a neurologist and the author of The Mind Electric, out from Simon & Schuster in the U.S. and Little, Brown in the U.K. Her stories and essays have appeared in the Los Angeles Review of Books, Time Magazine, The Boston Globe, The Washington Post, The New York Times, Ploughshares, and elsewhere. She is a graduate of Yale University and Stanford Medical School, and she trained in neurology, neuro-infectious diseases, and neuroimmunology at the Johns Hopkins Hospital and the Massachusetts General Hospital. She is now an Assistant Professor of Neurology at the Boston University School of Medicine, and she cares for patients at the Boston Medical Center. ­­Read Prias's story “The Elephant's Child” in The Common at thecommononline.org/the-elephants-child. Order The Mind Electric in all formats via Simon & Schuster at simonandschuster.com/books/The-Mind-Electric/. Learn more about Pria at www.priaanand.com. The Common is a print and online literary magazine publishing stories, essays, and poems that deepen our collective sense of place. On our podcast and in our pages, The Common features established and emerging writers from around the world. Read more and subscribe to the magazine at thecommononline.org, and follow us on Instagram, Bluesky, and Facebook. Emily Everett is managing editor of the magazine and host of the podcast. Her new debut novel All That Life Can Afford is the Reese's Book Club pick for April 2025. Her work has appeared in The New York Times Modern Love column, the Kenyon Review, Electric Literature, Tin House, and Mississippi Review. She was a 2022 Massachusetts Cultural Council Fellow in Fiction. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Pria Anand speaks to managing editor Emily Everett about her story “The Elephant's Child,” which appears in The Common's spring issue. The piece is a vivid retelling of a Hindu myth, the origin story of the elephant-headed god Ganesh. Pria talks about the process of writing and revising many versions of this ancient myth, why she felt inspired by it, and how her literary writing intersects with her career as a neurologist. Pria also discusses her debut book, The Mind Electric: A Neurologist on the Strangeness and Wonder of Our Brains, out this month from Simon & Schuster. The book explores how story and storytelling can illuminate the rich, complex gray areas within the science of the brain, weaving case study, history, fable, and memoir. Pria Anand is a neurologist and the author of The Mind Electric, out from Simon & Schuster in the U.S. and Little, Brown in the U.K. Her stories and essays have appeared in the Los Angeles Review of Books, Time Magazine, The Boston Globe, The Washington Post, The New York Times, Ploughshares, and elsewhere. She is a graduate of Yale University and Stanford Medical School, and she trained in neurology, neuro-infectious diseases, and neuroimmunology at the Johns Hopkins Hospital and the Massachusetts General Hospital. She is now an Assistant Professor of Neurology at the Boston University School of Medicine, and she cares for patients at the Boston Medical Center. ­­Read Prias's story “The Elephant's Child” in The Common at thecommononline.org/the-elephants-child. Order The Mind Electric in all formats via Simon & Schuster at simonandschuster.com/books/The-Mind-Electric/. Learn more about Pria at www.priaanand.com. The Common is a print and online literary magazine publishing stories, essays, and poems that deepen our collective sense of place. On our podcast and in our pages, The Common features established and emerging writers from around the world. Read more and subscribe to the magazine at thecommononline.org, and follow us on Instagram, Bluesky, and Facebook. Emily Everett is managing editor of the magazine and host of the podcast. Her new debut novel All That Life Can Afford is the Reese's Book Club pick for April 2025. Her work has appeared in The New York Times Modern Love column, the Kenyon Review, Electric Literature, Tin House, and Mississippi Review. She was a 2022 Massachusetts Cultural Council Fellow in Fiction. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/literary-studies

Pria Anand speaks to managing editor Emily Everett about her story “The Elephant's Child,” which appears in The Common's spring issue. The piece is a vivid retelling of a Hindu myth, the origin story of the elephant-headed god Ganesh. Pria talks about the process of writing and revising many versions of this ancient myth, why she felt inspired by it, and how her literary writing intersects with her career as a neurologist. Pria also discusses her debut book, The Mind Electric: A Neurologist on the Strangeness and Wonder of Our Brains, out this month from Simon & Schuster. The book explores how story and storytelling can illuminate the rich, complex gray areas within the science of the brain, weaving case study, history, fable, and memoir. Pria Anand is a neurologist and the author of The Mind Electric, out from Simon & Schuster in the U.S. and Little, Brown in the U.K. Her stories and essays have appeared in the Los Angeles Review of Books, Time Magazine, The Boston Globe, The Washington Post, The New York Times, Ploughshares, and elsewhere. She is a graduate of Yale University and Stanford Medical School, and she trained in neurology, neuro-infectious diseases, and neuroimmunology at the Johns Hopkins Hospital and the Massachusetts General Hospital. She is now an Assistant Professor of Neurology at the Boston University School of Medicine, and she cares for patients at the Boston Medical Center. ­­Read Prias's story “The Elephant's Child” in The Common at thecommononline.org/the-elephants-child. Order The Mind Electric in all formats via Simon & Schuster at simonandschuster.com/books/The-Mind-Electric/. Learn more about Pria at www.priaanand.com. The Common is a print and online literary magazine publishing stories, essays, and poems that deepen our collective sense of place. On our podcast and in our pages, The Common features established and emerging writers from around the world. Read more and subscribe to the magazine at thecommononline.org, and follow us on Instagram, Bluesky, and Facebook. Emily Everett is managing editor of the magazine and host of the podcast. Her new debut novel All That Life Can Afford is the Reese's Book Club pick for April 2025. Her work has appeared in The New York Times Modern Love column, the Kenyon Review, Electric Literature, Tin House, and Mississippi Review. She was a 2022 Massachusetts Cultural Council Fellow in Fiction. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/literature

Pria Anand speaks to managing editor Emily Everett about her story “The Elephant's Child,” which appears in The Common's spring issue. The piece is a vivid retelling of a Hindu myth, the origin story of the elephant-headed god Ganesh. Pria talks about the process of writing and revising many versions of this ancient myth, why she felt inspired by it, and how her literary writing intersects with her career as a neurologist. Pria also discusses her debut book, The Mind Electric: A Neurologist on the Strangeness and Wonder of Our Brains, out this month from Simon & Schuster. The book explores how story and storytelling can illuminate the rich, complex gray areas within the science of the brain, weaving case study, history, fable, and memoir. Pria Anand is a neurologist and the author of The Mind Electric, out from Simon & Schuster in the U.S. and Little, Brown in the U.K. Her stories and essays have appeared in the Los Angeles Review of Books, Time Magazine, The Boston Globe, The Washington Post, The New York Times, Ploughshares, and elsewhere. She is a graduate of Yale University and Stanford Medical School, and she trained in neurology, neuro-infectious diseases, and neuroimmunology at the Johns Hopkins Hospital and the Massachusetts General Hospital. She is now an Assistant Professor of Neurology at the Boston University School of Medicine, and she cares for patients at the Boston Medical Center. ­­Read Prias's story “The Elephant's Child” in The Common at thecommononline.org/the-elephants-child. Order The Mind Electric in all formats via Simon & Schuster at simonandschuster.com/books/The-Mind-Electric/. Learn more about Pria at www.priaanand.com. The Common is a print and online literary magazine publishing stories, essays, and poems that deepen our collective sense of place. On our podcast and in our pages, The Common features established and emerging writers from around the world. Read more and subscribe to the magazine at thecommononline.org, and follow us on Instagram, Bluesky, and Facebook. Emily Everett is managing editor of the magazine and host of the podcast. Her new debut novel All That Life Can Afford is the Reese's Book Club pick for April 2025. Her work has appeared in The New York Times Modern Love column, the Kenyon Review, Electric Literature, Tin House, and Mississippi Review. She was a 2022 Massachusetts Cultural Council Fellow in Fiction. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of The Healers Café, Manon Bolliger, FCAH, RBHT (facilitator and retired naturopath with 30+ years of practice) speaks to Dr. Eva Selhub: A Journey of Healing and Transformation - From Harvard Medical School to Holistic Resiliency, Exploring the Power of Mind-Body Medicine, Personal Growth, and Empowering Patients Through Curiosity, Compassion, and Innovative Approaches to Health and Well-being.   For the transcript and full story go to: https://www.drmanonbolliger.com/dr-eva-selhub        Highlights from today's episode include:   A transformative conversation with Dr. Eva Selhub, exploring her journey from traditional medicine to holistic healing, revealing how resilience, curiosity, and empowerment can reshape our approach to health and personal growth.   Dr. Selhub's emphasis on empowering patients and clients rather than keeping them in a victim mindset   Manon Bolliger we can definitely explore questions so that that they're thinking what other choices might be available to them, and it may position the work with fascia and with Bowen in a very positive light   ABOUT DR. EVA SELHUB: Dr. Eva Selhub is an internationally recognized resiliency expert  thought leader, physician, author, executive coach, keynote speaker, and spiritual advisor. With almost three decades of experience, she previously held roles as an Instructor of Medicine at Harvard Medical School and as a Clinical Associate at the prestigious Benson Henry Institute for Mind-Body Medicine at Massachusetts General Hospital, where she also served as Medical Director for six years. Dr. Selhub also served as an adjunct scientist of neuroscience at Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, one of six human nutrition research centers supported by the United States Department of Agriculture (USDA).   Dr. Selhub now collaborates with clients and organizations, leveraging her expertise to redefine leadership and wellbeing paradigms. Dr. Selhub possesses a unique talent for distilling complex scientific and spiritual concepts into practical, accessible knowledge. Her transformative energy, intuitive guidance, scientific expertise, and practical mindset inspire profound change and growth in her clients and audiences worldwide.  She is the author of six books, including: Burnout for Dummies, Resilience for Dummies, Your Health Destiny, The Stress Management Handbook, The Love Response.  Additionally, she co-authored:  Your Brain on Nature and has been featured in esteemed publications like The New York Times, authored multiple scientific publications, and has been showcased on national and international media platforms. Core purpose/passion: I want to bring hope to humanity of the infinite possibilities that are available to us to  heal and live a full and rich life. That magic can be normal. Website | Facebook | LinkedIn | Instagram | YouTube | TikTok | Twitter   ABOUT MANON BOLLIGER, FCAH, RBHT  As a de-registered (2021) board-certified naturopathic physician & in practice since 1992, I've seen an average of 150 patients per week and have helped people ranging from rural farmers in Nova Scotia to stressed out CEOs in Toronto to tri-athletes here in Vancouver.  My resolve to educate, empower and engage people to take charge of their own health is evident in my best-selling books:  'What Patients Don't Say if Doctors Don't Ask: The Mindful Patient-Doctor Relationship' and 'A Healer in Every Household: Simple Solutions for Stress'.  I also teach BowenFirst™ Therapy through and hold transformational workshops to achieve these goals.  So, when I share with you that LISTENING to Your body is a game changer in the healing process, I am speaking from expertise and direct experience"  Manon's Mission: A Healer in Every Household!  For more great information to go to her weekly blog:  http://bowencollege.com/blog.  For tips on health & healing go to: https://www.drmanonbolliger.com/tips    Follow Manon on Social – Facebook | Instagram | LinkedIn | YouTube | Twitter | Linktr.ee | Rumble   ABOUT THE HEALERS CAFÉ:  Manon's show is the #1 show for medical practitioners and holistic healers to have heart to heart conversations about their day to day lives.  Subscribe and review on your favourite platform: iTunes | Google Play | Spotify | Libsyn | iHeartRadio | Gaana | The Healers Cafe | Radio.com | Medioq |   Follow The Healers Café on FB: https://www.facebook.com/thehealerscafe   Remember to subscribe if you like our videos. Click the bell if you want to be one of the first people notified of a new release.   * De-Registered, revoked & retired naturopathic physician after 30 years of practice in healthcare. Now resourceful & resolved to share with you all the tools to take care of your health & vitality!  

If you're a physician with at least 5 years of experience looking for a flexible, non-clinical, part-time medical-legal consulting role… ...Dr. Armin Feldman's Medical Legal Coaching program will guarantee to add $100K in additional income within 12 months without doing any expert witness work. Any doctor in any specialty can do this work. And if you don't reach that number, he'll work with you for free until you do, guaranteed. How can he make such a bold claim? It's simple, he gets results…  Dr. David exceeded his clinical income without sacrificing time in his full-time position. Dr. Anke retired from her practice while generating the same monthly consulting income.  And Dr. Elliott added meaningful consulting work without lowering his clinical income or job satisfaction. So, if you're a physician with 5+ years of experience and you want to find out exactly how to add $100K in additional consulting income in just 12 months, go to arminfeldman.com.                                                          =============== Learn the business and management skills you need by enrolling in the University of Tennessee Physician Executive MBA program at nonclinicalphysicians.com/physicianmba. Get the FREE GUIDE to 10 Nonclinical Careers at nonclinicalphysicians.com/freeguide. Get a list of 70 nontraditional jobs at nonclinicalphysicians.com/70jobs.                                                                                                 =============== In this episode, Dr. J. Jordan Romano shares how he built a successful expert witness consulting career alongside his work as an internal medicine hospitalist at Harvard and Massachusetts General Hospital. What began with a colleague's request turned into a decade-long path that now allows him to apply his clinical expertise in legal settings while maintaining a full-time medical role. He explains how to get started in the field, including building connections, meeting qualification standards, and understanding that most cases are resolved before trial, making this a realistic way to expand both income and career opportunities. You'll find links mentioned in the episode at  nonclinicalphysicians.com/why-become-an-expert-witness/

Welcome back to Home Base Nation! This is our sixth episode in a series where we talk with some of the folks at Home Base who wake up every day with the same mission in mind, regardless of their role at the Center of Excellence in the Navy Yard and beyond. Over the next several weeks, we will share the staff conversations I had with some of the hardworking professionals at Home Base who help treat the invisible wounds of veterans and military families. We have published 120 episodes since 2019. For this new season, we thought it would be a good idea to look back on some of the highlights of our conversations and select 20 episodes that resonated with veterans, service members, military families, and the civilians who support them.But first up, you'll hear from some of the folks at Home Base who wake up every day with the same mission in mind, no matter what they do at the Center of Excellence in the Navy Yard and beyond. For this episode, you will hear a brief conversation with Registered Dietitian and Manager of Clinical and Culinary Nutrition for the Home Base Program Nicolette Maggiolo, serving those in the Home Base Intensive Clinical Program, New England Warrior Health & Fitness Program, and Outpatient Clinic. Additionally, Nicolette has authored a Limited edition Home Base Cookbook that features over 100 original recipes with reflections from veterans and military families. With all proceeds benefiting Home Base. It even has a bonus dog treat recipe for your pup, honoring our beloved Home Base dog Gatsby.  Woof. The cookbook was available at Stop and Shop in honor of Military Appreciation Month and once more become available we will share it here.Following my conversation with Nicolette, you'll hear an episode with Rock DJ and podcast host Mistress Carrie. A vehement supporter of U.S. troops and veterans, Mistress Carrie wanted to find a way to give back, and in 2006 she made her way to Iraq, as the first non-news journalist embedded with troops there, before "deploying" for a second time in Afghanistan in 2011, where she met Brigadier General (Ret.) Jack Hammond, who was leading command in Kabul at the time. Back in 2022, she stopped by the Home Base Center of Excellence to speak with Ron and General Hammond to speak about why supporting veterans matters so much and how she views service. Run To Home Base: Join Ron and his team and sign up individually or on another team at the 16th annual Run To Home Base on July 26th, 2025, at Fenway Park! Go to runtohomebase.orgPlease visit homebase.org for updates, programming, and resources if you or someone you know is struggling. Home Base Nation is the official podcast for the Home Base Program for Veterans and Military Families. Our team sees veterans, service members, and their families addressing the invisible wounds of war at no cost. This is all made possible thanks to a grateful nation. To learn more about how to help, visit us at www.homebase.org. If you or anyone you know would like to connect to care, you can also reach us at 617-724-5202.Follow Home Base on Twitter, Facebook, Instagram, LinkedInThe Home Base Nation Team is Steve Monaco, Army Veteran Kelly Field, Justin Scheinert, Chuck Clough, with COO Michael Allard, Brigadier General Jack Hammond, and Peter Smyth.Producer and Host: Dr. Ron HirschbergAssistant Producer, Editor: Chuck CloughChairman, Home Base Media Lab: Peter SmythThe views expressed by guests on the Home Base Nation podcast are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent. Views and opinions expressed by guests are those of the guests and do not necessarily reflect the views of the Massachusetts General Hospital, Home Base, the Red Sox Foundation, or any of its officials. 

What we eat matters—but emerging research suggests that when we eat is just as critical. Timing meals in sync with the body's circadian rhythm may influence metabolism, sleep, and even long-term health outcomes.In the latest episode of the DNS Podcast, we're exploring the intersection of circadian rhythm, chrononutrition, and home nutrition support with leading expert Dr. Hassan S. Dashti—Assistant Professor at Massachusetts General Hospital and Harvard Medical School.

AGORACOM TALKS Weekly RoundupCatch up on the small-cap breakthroughs driving battery innovation, environmental restoration, medical imaging, and resource expansion:HPQ Silicon (TSX-V: HPQ) (HPQFF: OTCQB) Begins Industrial Battery Production Using Breakthrough Silicon Anode TechHPQ Silicon and French partner Novacium have moved from lab success to industrial production, launching next-gen lithium-ion battery cells with GEN3 silicon anode tech. The cells boast up to 6,000 mAh and over 1,000 cycles, aimed at mobility, telecom, and defense. With production underway in Europe and a North American license in hand, HPQ is set to capitalize on surging energy storage demand—marking a clear transition from R&D to revenue.Zefiro Methane (CBOE Canada: ZEFI)(OTCQB: ZEFIF)USD $19.6M State Contract Secured Zefiro Methane has locked in a $19.6M, 3-year contract with the State of Ohio to plug ~200 leaking oil and gas wells. Through its subsidiary, Plants & Goodwin, the company will lead the high-impact project under a CMAR structure—tackling methane emissions while creating local jobs. With federal funds backing the effort, Zepheero is now a key player in the cleanup economy, turning environmental liability into long-term opportunity.Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM)First Multiple Sclerosis Patient ScannedQuantum BioPharma and Massachusetts General Hospital have completed the first scan of an MS patient using a novel PET tracer for demyelination. This could be a game-changer for tracking disease progression and accelerating trials for Quantum's lead MS therapy, Lucid-21-302. The advanced imaging could enable real-time measurement of treatment impact—bringing clarity to one of neurology's toughest challenges.Draganfly (NASDAQ: DPRO) (CSE: DPRO)100% Success in U.S. Army Trials — Autonomous Drone Logistics Takes FlightDraganfly's Commander 3XL drone, equipped with TB2's DROPS system, achieved flawless results in U.S. Army field trials. The system autonomously executed tactical resupply missions—pickup, delivery, docking, and recharging—without human input. With battlefield logistics moving toward full autonomy, this test cements Draganfly's role in reshaping military support operations for the 21st century.NexGold (TSXV: NEXG) (OTCQX: NXGCF)Goldboro Drilling Delivers High-Grade Hits - 1.60 g/t over 36.80m, including 53.57 g/t over 0.60mNexGold's 25,000-metre drill campaign at the Goldboro Project continues to impress, with infill holes intersecting 1.60 g/t over 36.80m, including 53.57 g/t over 0.60m. These results improve confidence in the resource model and could lead to upgraded classifications ahead of a feasibility update in late 2025. With permitting milestones also advancing, Goldboro is shaping into a leading near-term gold development story in Atlantic Canada.That's a wrap for this week. Follow us for more small-cap headlines and investor intelligence.

My conversation with Dr Dua begins at about 35 mins Stand Up is a daily podcast. I book,host,edit, post and promote new episodes with brilliant guests every day. This show is Ad free and fully supported by listeners like you! Please subscribe now for as little as 5$ and gain access to a community of over 750 awesome, curious, kind, funny, brilliant, generous souls Healthcare For Action was founded in 2022 to support healthcare workers running for Congress. Dr. Anahita Dua, Chair of Healthcare for Action, is a Vascular Surgeon at Massachusetts General Hospital and an Associate Professor of Surgery at Harvard University. As a surgeon, she knows that in order to get things done and save lives, the surgery team has to work together and take action. Our politics shouldn't be any different.  In 2023, Healthcare For Action merged with Doctors In Politics, founded in 2020 by a group of physicians specializing in psychiatry, family medicine, OBGYN, and neurology. They were committed to patient-centered and equitable political change at all levels of government and grew to a membership of nearly 10,000. We believe fundamentally that all policy is health policy.  There are too many existential threats facing our democracy. From reversing climate change, preserving access to abortion, and curbing the epidemic of gun violence we must take action now and play the long game. From acute care to prevention, healthcare workers know how to get the job done. That is the guiding vision of the largest Democratic healthcare workers PAC in the country - Join our community at Healthcare For Action! Anahita Dua, MD, MS, MBA, FACS, is a vascular surgeon at Massachusetts General Hospital and an associate professor of Surgery at Harvard Medical School. At Mass General, she is the director of the Vascular Lab, co-director of the Peripheral Artery Disease Center and Limb Evaluation and Amputation Program (LEAPP), associate director of the Wound Care Center, director of the Lymphedema Center and associate director of the Vascular Surgery Clerkship and director of clinical research for the division of vascular surgery. She specializes in advanced endovascular (minimally invasive) and traditional (open) limb salvage techniques for treating peripheral arterial disease and critical limb ischemia, diabetic limb disease, aortic disease, carotid disease, thoracic outlet syndrome and venous disease. Dr. Dua completed her vascular surgery fellowship at Stanford University Hospital, her general surgery residency at the Medical College of Wisconsin and her medical school in the United Kingdom. She has also completed a master's degree in trauma sciences, a master's in business administration in health care management and has a certificate in health economics and outcomes research as well as a certificate in drug and device development from the Massachusetts Institute of Technology. She is board-certified in vascular surgery, general surgery and advanced wound care and management. Dr. Dua has published over 140 peer reviewed papers and has edited five vascular surgery medical textbooks. She serves on multiple national vascular surgery committees through the Society for Vascular Surgery and other vascular organizations including the South Asian-American Vascular Society and American College of Surgeons. Dr. Dua's lab focuses on anticoagulation and biomarkers that are predictive of thrombosis and hemostasis in patients that have undergone revascularization. She is interested in creation precision, point of care medical approaches to anticoagulation for patients post revascularization. Her clinical and outcomes research focuses primarily on diseases involving peripheral vascular disease, limb salvage and critical limb ischemia. She is part of a technology development team that creates tools to increase walking distance and wound healing while decreasing pain in patients with peripheral vascular disease. Dr. Dua is also involved heavily in surgical outcomes-based research using large medical databases to generate both quality outcomes and cost effectiveness data. Dr. Dua is a self-described animal lover and rescuer of pitbulls. At one point, she housed 14 pitbull puppies and their mother at once. Nowadays, her spare time is spent with her husband, son, daughter and dog Leo. Join us Monday and Thursday's at 8EST for our  Bi Weekly Happy Hour Hangout!  Pete on Blue Sky Pete on Threads Pete on Tik Tok Pete on YouTube  Pete on Twitter Pete On Instagram Pete Personal FB page Stand Up with Pete FB page All things Jon Carroll  Follow and Support Pete Coe Buy Ava's Art  Hire DJ Monzyk to build your website or help you with Marketing  

It's summer and that means slathering yourself with sunblock before you're allowed to go run around outside. Not everyone loves that ritual: sunscreen can be cold or sticky. Sometimes it gets in your eyes, and it always feels like it's time to reapply JUST as you're about to jump in the water or go kick the ball. So, what's the deal? Is it really all that important? We get the scoop from Dr. Jeff Yu, a pediatric dermatologist at Massachusetts General Hospital. He'll help us understand: What is a sunburn? What's a tan? How does sunscreen work? How do you protect your eyes?Download our learning guides: PDF | Google Slide | Transcript

First up on the podcast, Staff Writer Erik Stokstad talks with host Sarah Crespi about how scientists are probing the world's hottest forests to better understand how plants will cope with climate change. His story is part of a special issue on plants and heat, which includes reviews and perspectives on the fate of plants in a warming world.   Next on the show, “convergent” antibodies may underlie the growing number of people allergic to peanuts. Sarita Patil, co-director of the Food Allergy Center at Massachusetts General Hospital and assistant professor at Harvard Medical School, joins the podcast to discuss her research on allergies and antibodies. She explains how different people appear to create antibodies with similar gene sequences and 3D structures that react to peanut proteins—a big surprise given the importance of randomness in the immune system's ability to recognize harmful invaders.   This week's episode was produced with help from Podigy.   About the Science Podcast   Authors: Sarah Crespi; Erik Stokstad Learn more about your ad choices. Visit megaphone.fm/adchoices

First up on the podcast, Staff Writer Erik Stokstad talks with host Sarah Crespi about how scientists are probing the world's hottest forests to better understand how plants will cope with climate change. His story is part of a special issue on plants and heat, which includes reviews and perspectives on the fate of plants in a warming world.   Next on the show, “convergent” antibodies may underlie the growing number of people allergic to peanuts. Sarita Patil, co-director of the Food Allergy Center at Massachusetts General Hospital and assistant professor at Harvard Medical School, joins the podcast to discuss her research on allergies and antibodies. She explains how different people appear to create antibodies with similar gene sequences and 3D structures that react to peanut proteins—a big surprise given the importance of randomness in the immune system's ability to recognize harmful invaders.   This week's episode was produced with help from Podigy.   About the Science Podcast   Authors: Sarah Crespi; Erik Stokstad Learn more about your ad choices. Visit megaphone.fm/adchoices

We have published 120 episodes since 2019. For this new season, we thought it would be a good idea to look back on some of the highlights of our conversations and select 20 episodes that resonated with veterans, service members, military families, and the civilians who support them.But first up, you'll hear from some of the folks at Home Base who wake up every day with the same mission in mind, no matter what they do at the Center of Excellence in the Navy Yard and beyond. Welcome back to Home Base Nation! For this episode, you will hear a brief conversation with Air Force Veteran and Family Support Team Manager, Stacie Frederiksson, who has worked in the non-profit arena serving veterans and their families for the past 15 years. Stacie served 14 years on active duty in the Air Force as an intelligence officer, supporting flying and space operations, before transferring to the Air Force Reserves, where she spent the last 9 years of her career at USCYBERCOM, retiring in 2016.Following the conversation with Stacie, you'll hear an episode featuring award-winning storyteller and filmmaker Spike Lee, recorded in London, England, in 2019. Home Base caught up with the legendary director before the first-ever Red Sox–Yankees game at the London Stadium. Although we were not happy with the series outcome, Mr. Lee was indeed a lifelong Yankee fan. Ron and Spike discuss some of the history of service by Black Americans and get a preview of his Vietnam War Film, early released at the time, Da5Bloods.Many thanks to Stacie Frederiksson for all her work at Home Base in support of this mission to stomp stigma and treat the invisible wounds of veterans and military families.Run To Home Base: Join Ron and his team and sign up individually or on another team at the 16th annual Run To Home Base on July 26th, 2025, at Fenway Park! Go to runtohomebase.orgPlease visit homebase.org for updates, programming, and resources if you or someone you know is struggling. Home Base Nation is the official podcast for the Home Base Program for Veterans and Military Families. Our team sees veterans, service members, and their families addressing the invisible wounds of war at no cost. This is all made possible thanks to a grateful nation. To learn more about how to help, visit us at www.homebase.org. If you or anyone you know would like to connect to care, you can also reach us at 617-724-5202.Follow Home Base on Twitter, Facebook, Instagram, LinkedInThe Home Base Nation Team is Steve Monaco, Army Veteran Kelly Field, Justin Scheinert, Chuck Clough, with COO Michael Allard, Brigadier General Jack Hammond, and Peter Smyth.Producer and Host: Dr. Ron HirschbergAssistant Producer, Editor: Chuck CloughChairman, Home Base Media Lab: Peter SmythThe views expressed by guests on the Home Base Nation podcast are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent. Views and opinions expressed by guests are those of the guests and do not necessarily reflect the views of the Massachusetts General Hospital, Home Base, the Red Sox Foundation, or any of its officials. 

Dr Jessica J Lin from Massachusetts General Hospital in Boston and Dr Joel W Neal from Stanford Cancer Institute in California summarize major treatment advances over the past year and review relevant ongoing clinical trials using targeted therapies for patients with non-small cell lung cancer. CME information and select publications here.

Today, Dr. Kat speaks with Dr. Lee Cohen about his powerful new documentary, More Than Blue. Dr. Cohen shares the inspiration behind the film, how it was made, and his hopes for its impact in destigmatizing perinatal mental health conditions. A passionate advocate, Dr. Cohen offers insights from his decades of work helping women navigate mood and anxiety disorders during and after pregnancy. Please check out the trailer for More Than Blue here: https://womensmentalhealth.org/more-than-blue-documentary/   Bio Dr. Cohen: Dr. Lee Cohen is Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital and Professor of Psychiatry at Harvard Medical School. A pioneer in perinatal and reproductive psychiatry, Dr. Cohen has dedicated his career to research, clinical care, and education focused on mental health across the female reproductive lifespan. He has authored over 350 publications in journals including JAMA and the American Journal of Psychiatry, and has received multiple awards for his contributions to maternal mental health. Dr. Cohen is a nationally recognized leader and a passionate voice in improving care for women with perinatal mood and anxiety disorders. Show Highlights: Dr. Cohen's journey in women's mental health The key is getting patients well during pregnancy. Today's trends in perinatal mental health, from Dr. Cohen's perspective as a researcher and clinician Increasing awareness also increases access to care for at-risk patients. Accessing care doesn't always result in “well” patients several months later. Planning process for the “More Than Blue” documentary Characteristics of patients with PMADs  Process of collecting, curating, and organizing diverse stories via⁠⁠ womensmentalhealth.org⁠⁠ to destigmatize treatment options and show multiple perspectives Dr. Cohen's perspective on the importance of including postpartum psychosis in the documentary (A YouTube video is in the works.) Dr. Cohen's passion and optimism for his work: “We're not done.” The intentional plan for screenings and dissemination of “More Than Blue”  “Lowering the burden” in helping people feel comfortable in telling their stories to optimize the likelihood of proper care Resources: Connect with Dr. Cohen: The Center for⁠⁠ Women's Mental Health at MGH⁠⁠,⁠⁠ Facebook⁠⁠, ⁠⁠Instagram⁠⁠, and⁠⁠ X⁠⁠. Womensmentalhealth.org Call the National Maternal Mental Health Hotline at 1-833-TLC-MAMA or visit⁠⁠ cdph.ca.gov⁠⁠ Please find resources in English and Spanish at⁠⁠ Postpartum Support International⁠⁠, or contact us by phone or text at 1-800-944-4773. There are many free resources available, including online support groups, peer mentors, a specialist provider directory, and perinatal mental health training for therapists, physicians, nurses, doulas, and anyone who wants to become more supportive in offering services.  You can also follow PSI on social media, including⁠⁠ Instagram⁠⁠,⁠⁠ Facebook⁠⁠, and other platforms. Visit⁠⁠ www.postpartum.net/professionals/certificate-trainings/⁠⁠ for information on the grief course.   Visit my website at⁠⁠ www.wellmindperinatal.com⁠⁠ for more information, resources, and courses you can take today!If you are a California resident seeking a therapist in perinatal mental health, please ⁠⁠email me⁠⁠ about openings for private pay clients. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Dr. Nathan Pennell and Dr. Cheryl Czerlanis discuss challenges in lung cancer screening and potential solutions to increase screening rates, including the use of AI to enhance risk prediction and screening processes. Transcript Dr. Nate Pennell: Hello, and welcome to By the Book, a monthly podcast series for ASCO Education that features engaging discussions between editors and authors from the ASCO Educational Book. I'm Dr. Nate Pennell, the co-director of the Cleveland Clinic Lung Cancer Program and vice chair of clinical research for the Taussig Cancer Center. I'm also the editor-in-chief for the ASCO Educational Book.  Lung cancer is one of the leading causes of cancer-related mortality worldwide, and most cases are diagnosed at advanced stages where curative treatment options are limited. On the opposite end, early-stage lung cancers are very curable. If only we could find more patients at that early stage, an approach that has revolutionized survival for other cancer types such as colorectal and breast cancer.  On today's episode, I'm delighted to be joined by Dr. Cheryl Czerlanis, a professor of medicine and thoracic medical oncologist at the University of Wisconsin Carbone Cancer Center, to discuss her article titled, "Broadening the Net: Overcoming Challenges and Embracing Novel Technologies in Lung Cancer Screening." The article was recently published in the ASCO Educational Book and featured in an Education Session at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Cheryl, it's great to have you on the podcast today. Thanks for being here. Dr. Cheryl Czerlanis: Thanks, Nate. It's great to be here with you. Dr. Nate Pennell: So, I'd like to just start by asking you a little bit about the importance of lung cancer screening and what evidence is there that lung cancer screening is beneficial. Dr. Cheryl Czerlanis: Thank you. Lung cancer screening is extremely important because we know that lung cancer survival is closely tied to stage at diagnosis. We have made significant progress in the treatment of lung cancer, especially over the past decade, with the introduction of immunotherapies and targeted therapies based on personalized evaluation of genomic alterations. But the reality is that outside of a lung screening program, most patients with lung cancer present with symptoms related to advanced cancer, where our ability to cure the disease is more limited.  While lung cancer screening has been studied for years, the National Lung Screening Trial, or the NLST, first reported in 2011 a significant reduction in lung cancer deaths through screening. Annual low-dose CT scans were performed in a high-risk population for lung cancer in comparison to chest X-ray. The study population was comprised of asymptomatic persons aged 55 to 74 with a 30-pack-year history of smoking who were either active smokers or had quit within 15 years. The low-dose CT screening was associated with a 20% relative risk reduction in lung cancer-related mortality. A similar magnitude of benefit was also reported in the NELSON trial, which was a large European randomized trial comparing low-dose CT with a control group receiving no screening. Dr. Nate Pennell: So, this led, of course, to approval from CMS (Centers for Medicare and Medicaid Services) for lung cancer screening in the Medicare population, probably about 10 years ago now, I think. And there are now two major trials showing an unequivocal reduction in lung cancer-related mortality and even evidence that it reduces overall mortality with lung cancer screening. But despite this, lung cancer screening rates are very low in the United States. So, first of all, what's going on? Why are we not seeing the kinds of screening rates that we see with mammography and colonoscopy? And what are the barriers to that here? Dr. Cheryl Czerlanis: That's a great question. Thank you, Nate. In the United States, recruitment for lung cancer screening programs has faced numerous challenges, including those related to socioeconomic, cultural, logistical, and even racial disparities. Our current lung cancer screening guidelines are somewhat imprecise and often fail to address differences that we know exist in sex, smoking history, socioeconomic status, and ethnicity. We also see underrepresentation in certain groups, including African Americans and other minorities, and special populations, including individuals with HIV. And even where lung cancer screening is readily available and we have evidence of its efficacy, uptake can be low due to both provider and patient factors. On the provider side, barriers include having insufficient time in a clinic visit for shared decision-making, fear of missed test results, lack of awareness about current guidelines, concerns about cost, potential harms, and evaluating both true and false-positive test results.  And then on the patient side, barriers include concerns about cost, fear of getting a cancer diagnosis, stigma associated with tobacco smoking, and misconceptions about the treatability of lung cancer. Dr. Nate Pennell: I think those last two are really what make lung cancer unique compared to, say, for example, breast cancer, where there really is a public acceptance of the value of mammography and that breast cancer is no one's fault and that it really is embraced as an active way you can take care of yourself by getting your breast cancer screening. Whereas in lung cancer, between the stigma of smoking and the concern that, you know, it's a death sentence, I think we really have some work to be made up, which we'll talk about in a minute about what we can do to help improve this.  Now, that's in the U.S. I think things are probably, I would imagine, even worse when we leave the U.S. and look outside, especially at low- and middle-income countries. Dr. Cheryl Czerlanis: Yes, globally, this issue is even more complex than it is in the United States. Widespread implementation of low-dose CT imaging for lung cancer screening is limited by manpower, infrastructure, and economic constraints. Many low- and middle-income countries even lack sufficient CT machines, trained personnel, and specialized facilities for accurate and timely screenings. Even in urban centers with advanced diagnostic facilities, the high screening and follow-up care costs can limit access. Rural populations face additional barriers, such as geographic inaccessibility of urban centers, transportation costs, language barriers, and mistrust of healthcare systems. In addition, healthcare systems in these regions often prioritize infectious diseases and maternal health, leaving limited room for investments in noncommunicable disease prevention like lung cancer screening. Policymakers often struggle to justify allocating resources to lung cancer screening when immediate healthcare needs remain unmet. Urban-rural disparities exacerbate these challenges, with rural regions frequently lacking the infrastructure and resources to sustain screening programs. Dr. Nate Pennell: Well, it's certainly an intimidating problem to try to reduce these disparities, especially between the U.S. and low- and middle-income countries. So, what are some of the potential solutions, both here in the U.S. and internationally, that we can do to try to increase the rates of lung cancer screening? Dr. Cheryl Czerlanis: The good news is that we can take steps to address these challenges, but a multifaceted approach is needed. Public awareness campaigns focused on the benefits of early detection and dispelling myths about lung cancer screening are essential to improving participation rates. Using risk-prediction models to identify high-risk individuals can increase the efficiency of lung cancer screening programs. Automated follow-up reminders and screening navigators can also ensure timely referrals and reduce delays in diagnosis and treatment. Reducing or subsidizing the cost of low-dose CT scans, especially in low- or middle-income countries, can improve accessibility. Deploying mobile CT scanners can expand access to rural and underserved areas.  On a global scale, integrating lung cancer screening with existing healthcare programs, such as TB or noncommunicable disease initiatives, can enhance resource utilization and program scalability. Implementing lung cancer screening in resource-limited settings requires strategic investment, capacity building, and policy interventions that prioritize equity. Addressing financial constraints, infrastructure gaps, and sociocultural barriers can help overcome existing challenges. By focusing on cost-effective strategies, public awareness, and risk-based eligibility criteria, global efforts can promote equitable access to lung cancer screening and improve outcomes.  Lastly, as part of the medical community, we play an important role in a patient's decision to pursue lung cancer screening. Being up to date with current lung cancer screening recommendations, identifying eligible patients, and encouraging a patient to undergo screening often is the difference-maker. Electronic medical record (EMR) systems and reminders are helpful in this regard, but relationship building and a recommendation from a trusted provider are really essential here. Dr. Nate Pennell: I think that makes a lot of sense. I mean, there are technology improvements. For example, our lung cancer screening program at The Cleveland Clinic, a few years back, we finally started an automated best practice alert in our EMR for patients who met the age and smoking requirements, and it led to a six-fold increase in people referred for screening. But at the same time, there's a difference between just getting this alert and putting in an order for lung cancer screening and actually getting those patients to go and actually do the screening and then follow up on it. And that, of course, requires having that relationship and discussion with the patient so that they trust that you have their best interests. Dr. Cheryl Czerlanis: Exactly. I think that's important. You know, certainly, while technology can aid in bringing patients in, there really is no substitute for trust-building and a personal relationship with a provider. Dr. Nate Pennell: I know that there are probably multiple examples within the U.S. where health systems or programs have put together, I would say, quality improvement projects to try to increase lung cancer screening and working with their community. There's one in particular that you discuss in your paper called the "End Lung Cancer Now" initiative. I wonder if you could take us through that. Dr. Cheryl Czerlanis: Absolutely. "End Lung Cancer Now" is an initiative at the Indiana University Simon Comprehensive Cancer Center that has the vision to end suffering and death from lung cancer in Indiana through education and community empowerment. We discuss this as a paradigm for how community engagement is important in building and scaling a lung cancer screening program.  In 2023, the "End Lung Cancer Now" team decided to focus its efforts on scaling and transforming lung cancer screening rates in Indiana. They developed a task force with 26 experts in various fields, including radiology, pulmonary medicine, thoracic surgery, public health, and advocacy groups. The result of this work is an 85-page blueprint with key recommendations that any system and community can use to scale lung cancer screening efforts. After building strong infrastructure for lung cancer screening at Indiana University, they sought to understand what the priorities, resources, and challenges in their communities were. To do this, they forged strong partnerships with both local and national organizations, including the American Lung Association, American Cancer Society, and others. In the first year, they actually tripled the number of screening low-dose CTs performed in their academic center and saw a 40% increase system-wide. One thing that I think is the most striking is that through their community outreach, they learned that most people prefer to get medical care close to home within their own communities. Establishing a way to support the local infrastructure to provide care became far more important than recruiting patients to their larger system.  In exciting news, "End Lung Cancer Now" has partnered with the IU Simon Comprehensive Cancer Center and IU Health to launch Indiana's first and only mobile lung screening program in March of 2025. This mobile program travels around the state to counties where the highest incidence of lung cancer exists and there is limited access to screening. The mobile unit parks at trusted sites within communities and works in partnership, not competition, with local health clinics and facilities to screen high-risk populations. Dr. Nate Pennell: I think that sounds like a great idea. Screening is such an important thing that it doesn't necessarily have to be owned by any one particular health system for their patients. I think. And I love the idea of bringing the screening to patients where they are. I can speak to working in a regional healthcare system with a main campus in the downtown that patients absolutely hate having to come here from even 30 or 40 minutes away, and they'd much rather get their care locally. So that makes perfect sense.  So, under the current guidelines, there are certainly things that we can do to try to improve capturing the people that meet those. But are those guidelines actually capturing enough patients with lung cancer to make a difference? There certainly are proposals within patient advocacy communities and even other countries where there's a large percentage of non-smokers who perhaps get lung cancer. Can we expand beyond just older, current and heavy smokers to identify at-risk populations who could benefit from screening? Dr. Cheryl Czerlanis: Yes, I think we can, and it's certainly an active area of research interest. We know that tobacco is the leading cause of lung cancer worldwide. However, other risk factors include secondhand smoke, family history, exposure to environmental carcinogens, and pulmonary diseases like COPD and interstitial lung disease. Despite these known associations, the benefit of lung cancer screening is less well elucidated in never-smokers and those at risk of developing lung cancer because of family history or other risk factors. We know that the eligibility criteria associated with our current screening guidelines focus on age and smoking history and may miss more than 50% of lung cancers. Globally, 10% to 25% of lung cancer cases occur in never-smokers. And in certain parts of the world, like you mentioned, Nate, such as East Asia, many lung cancers are diagnosed in never-smokers, especially in women. Risk-prediction models use specific risk factors for lung cancer to enhance individual selection for screening, although they have historically focused on current or former smokers.  We know that individuals with family members affected by lung cancer have an increased risk of developing the disease. To this end, several large-scale, single-arm prospective studies in Asia have evaluated broadening screening criteria to never-smokers, with or without additional risk factors. One such study, the Taiwan Lung Cancer Screening in Never-Smoker Trial, was a multicenter prospective cohort study at 17 medical centers in Taiwan. The primary outcome of the TALENT trial was lung cancer detection rate. Eligible patients aged 55 to 75 had either never smoked or had a light and remote smoking history. In addition, inclusion required one or more of the following risk factors: family history of lung cancer, passive smoke exposure, history of TB or COPD, a high cooking index, which is a metric that quantifies exposure to cooking fumes, or a history of cooking without ventilation. Participants underwent low-dose CT screening at baseline, then annually for 2 years, and then every 2 years for up to 6 years. The lung cancer detection rate was 2.6%, which was higher than that reported in the NLST and NELSON trials, and most were stage 0 or I cancers. Subsequently, this led to the Taiwan Early Detection Program for Lung Cancer, a national screening program that was launched in 2022, targeting 2 screening populations: individuals with a heavy history of smoking and individuals with a family history of lung cancer.  We really need randomized controlled trials to determine the true rates of overdiagnosis or finding cancers that would not lead to morbidity or mortality in persons who are diagnosed, and to establish whether the high lung detection rates are associated with a decrease in lung cancer-related mortality in these populations. However, the implementation of randomized controlled low-dose CT screening trials in never-smokers has been limited by the need for large sample sizes, lengthy follow-up, and cost.  In another group potentially at higher risk for developing lung cancer, the role of lung cancer screening in individuals who harbor germline pathogenic variants associated with lung cancer also needs to be explored further. Dr. Nate Pennell: We had this discussion when the first criteria came out because there have always been risk-based calculators for lung cancer that certainly incorporate smoking but other factors as well and have discussion about whether we should be screening people based on their risk and not just based on discrete criteria such as smoking. But of course, the insurance coverage for screening, you have to fit the actual criteria, which is very constrained by age and smoking history. Do you think in the U.S. there's hope for broadening our screening beyond NLST and NELSON criteria? Dr. Cheryl Czerlanis: I do think at some point there is hope for broadening the criteria beyond smoking history and age, beyond the criteria that we have typically used and that is covered by insurance. I do think it will take some work to perhaps make the prediction models more precise or to really understand who can benefit. We certainly know that there are many patients who develop lung cancer without a history of smoking or without family history, and it would be great if we could diagnose more patients with lung cancer at an earlier stage. I think this will really count on there being some work towards trying to figure out what would be the best population for screening, what risk factors to look for, perhaps using some new technologies that may help us to predict who is at risk for developing lung cancer, and trying to increase the group that we study to try and find these early-stage lung cancers that can be cured. Dr. Nate Pennell: Part of the reason we, of course, try to enrich our population is screening works better when you have a higher pretest probability of actually having cancer. And part of that also is that our technology is not that great. You know, even in high-risk patients who have CT scans that are positive for a screen, we know that the vast majority of those patients with lung nodules actually don't have lung cancer. And so you have to follow them, you have to use various models to see, you know, what the risk, even in the setting of a positive screen, is of having lung cancer.  So, why don't we talk about some newer tools that we might use to help improve lung cancer screening? And one of the things that everyone is super excited about, of course, is artificial intelligence. Are there AI technologies that are helping out in early detection in lung cancer screening? Dr. Cheryl Czerlanis: Yes, that's a great question. We know that predicting who's at risk for lung cancer is challenging for the reasons that we talked about, knowing that there are many risk factors beyond smoking and age that are hard to quantify. Artificial intelligence is a tool that can help refine screening criteria and really expand screening access. Machine learning is a form of AI technology that is adept at recognizing patterns in large datasets and then applying the learning to new datasets. Several machine learning models have been developed for risk stratification and early detection of lung cancer on imaging, both with and without blood-based biomarkers. This type of technology is very promising and can serve as a tool that helps to select individuals for screening by predicting who is likely to develop lung cancer in the future.  A group at Massachusetts General Hospital, represented in our group for this paper by my co-authors, Drs. Fintelmann and Chang, developed Sybil, which is an open-access 3D convolutional neural network that predicts an individual's future risk of lung cancer based on the analysis of a single low-dose CT without the need for human annotation or other clinical inputs. Sybil and other machine learning models have tremendous potential for precision lung cancer screening, even, and perhaps especially, in settings where expert image interpretation is unavailable. They could support risk-adapted screening schedules, such as varying the frequency and interval of low-dose CT scans according to individual risk and potentially expand lung cancer screening eligibility beyond age and smoking history. Their group predicts that AI tools like Sybil will play a major role in decoding the complex landscape of lung cancer risk factors, enabling us to extend life-saving lung cancer screening to all who are at risk. Dr. Nate Pennell: I think that that would certainly be welcome. And as AI is working its way into pretty much every aspect of life, including medical care, I think it's certainly promising that it can improve on our existing technology.  We don't have to spend a lot of time on this because I know it's a little out of scope for what you covered in your paper, but I'm sure our listeners are curious about your thoughts on the use of other types of testing beyond CT screening for detecting lung cancer. I know that there are a number of investigational and even commercially available blood tests, for example, for detection of lung cancer, or even the so-called multi-cancer detection blood tests that are now being offered, although not necessarily being covered by insurance, for multiple types of cancer, but lung cancer being a common cancer is included in that. So, what do you think? Dr. Cheryl Czerlanis: Yes, like you mentioned, there are novel bioassays such as blood-based biomarker testing that evaluate for DNA, RNA, and circulating tumor cells that are both promising and under active investigation for lung cancer and multi-cancer detection. We know that such biomarker assays may be useful in both identifying lung cancers but also in identifying patients with a high-risk result who should undergo lung cancer screening by conventional methods. Dr. Nate Pennell: Anything that will improve on our rate of screening, I think, will be welcome. I think probably in the future, it will be some combination of better risk prediction and better interpretation of screening results, whether those be imaging or some combination of imaging and biomarkers, breath-based, blood-based. There's so much going on that it is pretty exciting, but we're still going to have to overcome the stigma and lack of public support for lung cancer screening if we're going to move the needle. Dr. Cheryl Czerlanis: Yes, I think moving the needle is so important because we know lung cancer is still a very morbid disease, and our ability to cure patients is not where we would like it to be. But I do believe there's hope. There are a lot of motivated individuals and groups who are passionate about lung cancer screening, like myself and my co-authors, and we're just happy to be able to share some ways that we can overcome the challenges and really try and make an impact in the lives of our patients. Dr. Nate Pennell: Well, thank you, Dr. Czerlanis, for joining me on the By the Book Podcast today and for all of your work to advance care for patients with lung cancer. Dr. Cheryl Czerlanis: Thank you, Dr. Pennell. It's such a pleasure to be with you today. Thank you. Dr. Nate Pennell: And thank you to our listeners for joining us today. You'll find a link to Dr. Czerlanis' article in the transcript of this episode.  Please join us again next month for By the Book's next episode and more insightful views on topics you'll be hearing at the education sessions from ASCO meetings throughout the year, and our deep dives on approaches that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:     Dr. Nathan Pennell    @n8pennell   @n8pennell.bsky.social Dr. Cheryl Czerlanis Follow ASCO on social media:     @ASCO on X (formerly Twitter)     ASCO on Bluesky    ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Nate Pennell:        Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron       Research Funding (Institution): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi    Dr. Cheryl Czerlanis: Research Funding (Institution): LungLife AI, AstraZeneca, Summit Therapeutics

We kicked off the program with four news stories and different guests on the stories we think you need to know about!Rappell Boston - 100 People To Brave The Side of One of Cambridge's Biggest Buildings to Fight Epilepsy on Saturday, June 14, 2025. Josh Drew - Director of Development at Epilepsy Foundation New England and is in charge of the Rappel Event talked with Dan about the event.Boulder, Colorado antisemitic attack that injured a dozen. Adam Katz - president of Foundation to Combat Antisemitism checked in.Is sunscreen toxic? The war on sunscreen! Timothy Rebbeck, a professor of cancer prevention at Dana-Farber Cancer Institute has the answer.At-Home Heart Attacks and Cardiac Deaths on the Rise Since COVID-19 Pandemic, a recent study finds. Dr. Jason Wasfy – author of the published study on this & director of Outcomes Research at the Massachusetts General Hospital Cardiology Division and a faculty member at the Mongan Institute at Massachusetts General Hospital checked in.Listen to WBZ NewsRadio on the NEW iHeart Radio app and be sure to set WBZ NewsRadio as your #1 preset!

We have published 120 episodes since 2019. For this new season, we thought it would be a good idea to look back on some of the highlights of our conversations and select 20 episodes that resonated with veterans, service members, military families, and the civilians who support them.But first up, you'll hear from some of the folks at Home Base who wake up every day with the same mission in mind, no matter what they do at the Center of Excellence in the Navy Yard and beyond. For this episode, you will hear a brief conversation with Marc Moyer, a U.S. Army Veteran who served with the 3rd Infantry Division in Iraq and is now a Veteran Outreach Coordinator at Home Base. Following my conversation with Marc, you'll hear an episode featuring Bonnie Carroll, a retired major in the Air Force Reserve and founder of the Tragedy Assistance Program for Survivors, also known as TAPS. This organization has created a vital support network for those mourning the loss of a military loved one.Many thanks to Marc Moyer for all his work at Home Base in support of this mission to stomp stigma and treat the invisible wounds of veterans and military families.Run To Home Base: Join Ron and his team and sign up individually or on another team at the 16th annual Run To Home Base on July 26th, 2025, at Fenway Park! Go to runtohomebase.orgPlease visit homebase.org for updates, programming, and resources if you or someone you know is struggling. Home Base Nation is the official podcast for the Home Base Program for Veterans and Military Families. Our team sees veterans, service members, and their families addressing the invisible wounds of war at no cost. This is all made possible thanks to a grateful nation. To learn more about how to help, visit us at www.homebase.org. If you or anyone you know would like to connect to care, you can also reach us at 617-724-5202.Follow Home Base on Twitter, Facebook, Instagram, LinkedInThe Home Base Nation Team is Steve Monaco, Army Veteran Kelly Field, Justin Scheinert, Chuck Clough, with COO Michael Allard, Brigadier General Jack Hammond, and Peter Smyth.Producer and Host: Dr. Ron HirschbergAssistant Producer, Editor: Chuck CloughChairman, Home Base Media Lab: Peter SmythThe views expressed by guests on the Home Base Nation podcast are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent. Views and opinions expressed by guests are those of the guests and do not necessarily reflect the views of the Massachusetts General Hospital, Home Base, the Red Sox Foundation, or any of its officials.

In this episode, Audible Bleeding Editors Sasank Kalipatnapu (@ksasank), Falen Demsas sit down with Dr. Rabih Chaer (@rchaer2), Dr. Michael Conte(@MichaelSConteMD), Dr. Sherene Shalhub and Dr. Malachi Sheahan III, the four SVS secretary candidates for this year to learn more about them as part of the ongoing election process.    Show links: SVS 2025 Meet the Secretary Candidates—Home Page—provides a comprehensive overview of all the candidates. Their professional biographies and answers to questions about their plans for the future are available in both text and video formats.   Show Guests: Dr. Rabih Chaer, Professor of Surgery and Chief of the Division of Vascular Surgery at Stony Brook University Dr. Michael Conte, Professor and Chief of the Division of Vascular & Endovascular Surgery at the University of California, San Francisco. Dr. Sherene Shalhub, Professor and Chief of the Division Vascular and Endovascular Surgery at Oregon Health & Science University (OHSU). Dr. Malachi Sheahan, Professor and Chair of the Division of Vascular and Endovascular Surgery at Louisiana State University Health Sciences Center in New Orleans. Sasank Kalipatnapu - PGY4 general surgery resident, University of Massachusetts Falen Demsas- PGY 3 integrated vascular surgery resident, Massachusetts General Hospital    Follow us @audiblebleeding Learn more about us at https://www.audiblebleeding.com/about-1/ and provide us with your feedback with our listener survey.

Ultra-processed foods now make up over half of what many of us eat - and the health consequences are only just coming into focus. In this episode, we reveal what's really happening inside your body when you eat these foods daily.  Our guest is Dr. Andy Chan, a Harvard professor and leading expert on gut health and cancer prevention. He heads the Clinical and Translational Epidemiology Unit at Massachusetts General Hospital and has published over 400 scientific papers. Dr. Chan breaks down the hidden links between UPFs, inflammation, and diseases like obesity, diabetes, and colorectal cancer. You'll hear why some foods that look healthy on the shelf may be doing long-term damage - and how the gut microbiome plays a crucial role in the process. This is the research big food companies don't want you to hear. If you care about what you and your family are eating, don't miss this conversation. Unwrap the truth about your food

Zirui Song is an associate professor of health care policy and medicine at Harvard Medical School and a general internist at Massachusetts General Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. Z. Song and J.M. Zhu. Primary Care — From Common Good to Free-Market Commodity. N Engl J Med 2025;392:1977-1979.

As artificial intelligence (AI) tools become increasingly mainstream, they can potentially transform neurology clinical practice by improving patient care and reducing clinician workload. Critically evaluating these AI tools for clinical practice is important for successful implementation. In this episode, Katie Grouse, MD, FAAN speaks with Peter Hadar, MD, MS, coauthor of the article “Clinical Applications of Artificial Intelligence in Neurology Practice” in the Continuum® April 2025 Neuro-ophthalmology issue. Dr. Grouse is a Continuum® Audio interviewer and a clinical assistant professor at the University of California San Francisco in San Francisco, California. Dr. Hadar is an instructor of neurology at Harvard Medical School and an attending physician at the Massachusetts General Hospital in Boston, Massachusetts. Additional Resources Read the article: Clinical Applications of Artificial Intelligence in Neurology Practice Subscribe to Continuum®: shop.lww.com/Continuum Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Guest: @PeterNHadar Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about subscribing to the journal, listening to verbatim recordings of the articles, and exclusive access to interviews not featured on the podcast. Dr Grouse: This is Dr Katie Grouse. Today I'm interviewing Dr Peter Hadar about his article on clinical applications of artificial intelligence in neurology practice, which he wrote with Dr Lydia Moura. This article appears in the April 2025 Continuum issue on neuro-ophthalmology. Welcome to the podcast, and please introduce yourself to our audience. Dr Hadar: Hi, thanks for having me on, Katie. My name is Dr Peter Hadar. I'm currently an instructor over at Mass General Hospital, Harvard Medical School, and I'm excited to talk more about AI and how it's going to change our world, hopefully for the better. Dr Grouse: We're so excited to have you. The application of AI in clinical practice is such an exciting and rapidly developing topic, and I'm so pleased to have you here to talk about your article, which I found to be absolutely fascinating. To start, I'd like to hear what you hope will be the key takeaway from your article with our listeners. Dr Hadar: Yeah, thank you. The main point of the article is that AI in medicine is a tool. It's a wonderful tool that we should be cautiously optimistic about. But the important thing is for doctors, providers to be advocates on their behalf and on behalf of their patients for the appropriate use of this tool, because there are promises and pitfalls just with any tool. And I think in the article we detail a couple ways that it can be used in diagnostics, in clinical documentation, in the workflow, all ways that can really help providers. But sometimes the devil is in the details. So, we get into that as well. Dr Grouse: How did you become interested in AI and its application, specifically in the practice of neurology? Dr Hadar: When I was a kid, as most neurologists are, I was- I nerded out on a lot of sci-fi books, and I was really into Isaac Asimov and some of his robotics, which kind of talks about the philosophy of AI and how AI will be integrated in the future. As I got into neurology, I started doing research neurology and a lot of folks, if you're familiar with AI and machine learning, statistics can overlap a lot with machine learning. So slowly but surely, I started using statistical methods, machine learning methods, in some of my neurology research and kind of what brought me to where I am today. Dr Grouse: And thinking about and talking about AI, could you briefly summarize a few important terms that we might be talking about, such as artificial intelligence, generative AI, machine learning, etcetera? Dr Hadar: It's a little difficult, because some of these terms are nebulous and some of these terms are used in the lay public differently than other folks would use it. But in general, artificial intelligence is kind of the ability of machines or computers to communicate independently. It's similar to as humans would do so. And there are kind of different levels of AI. There's this very hard AI where people are worried about with kind of terminator-full ability to replicate a human, effectively. And there are other forms of narrow AI, which are actually more of what we're talking about today, and where it's very kind of specific, task-based applications of machine learning in which even if it's very complex, the AI tools, the machine learning tools are able to give you a result. And just some other terms, I guess out there. You hear a lot about generative AI. There's a lot of these companies and different algorithms that incorporate generative AI, and that usually kind of creates something, kind of from scratch, based on a lot of data. So, it can create pictures, it can create new text if you just ask it. Other terms that can be used are natural language processing, which is a big part of some of the hospital records. When AI tools read hospital records and can summarize something, if it can translate things. So, it turns human speech into these results that you look for. And I guess other terms like large language models are something that also have come into prominence and they rely a lot on natural language processing, being able to understand human speech, interpret it and come up with the results that you want. Dr Grouse: Thank you, that's really helpful. Building on that, what are some of the current clinical applications of AI that we may already be using in our neurologic practice and may not even be aware that that's what that is? Dr Hadar: It depends on which medical record system you use, but a very common one are some of the clinical alerts that people might get, although some of them are pretty basic and they can say, you know, if the sodium is this level, you get an alert. But sometimes they do incorporate fancier machine learning tools to say, here's a red flag. You really should think about contacting the patient about this. And we can talk about it as well. It might encourage burnout with all the different flags. So, it's not a perfect tool. But these sorts of things, typically in the setting of alerts, are the most common use. Sorry, and another one is in folks who do stroke, there are a lot of stroke algorithms with imaging that can help detect where the strokes occur. And that's a heavy machine learning field of image processing, image analysis for rapid detection of stroke. Dr Grouse: That's really interesting. I think my understanding is that AI has been used specifically for radiology interpretation applications for some time now. Is that right? Dr Hadar: In some ways. Actually, my background is in neuroimaging analysis, and we've been doing a lot of it. I've been doing it for years. There's still a lot of room to go, but it's really getting there in some ways. My suspicion is that in the coming years, it's going to be similar to how anesthesiologists at one point were actively bagging people in the fifties, and then you develop machines that can kind of do it for you. At some point there's going to be a prelim radiology read that is not just done by the resident or fellow, but is done by the machine. And then another radiologist would double check it and make sure. And I think that's going to happen in our lifetime. Dr Grouse: Wow, that's absolutely fascinating. What are some potential applications of AI in neurologic practice that may be most high-yield to improve patient care, patient access, and even reduce physician burnout? Dr Hadar: These are separate sort of questions, but they're all sort of interlinked. I think one of the big aspects of patient care in the last few years, especially with the electronic medical record, is patients have become much more their own advocates and we focus a lot more on patient autonomy. So, they are reaching out to providers outside of appointments. This can kind of lead to physician burnout. You have to answer all these messages through the electronic medical record. And so having, effectively, digital twins of yourself, AI version of yourself, that can answer the questions for the patient on your off times is one of the things that can definitely help with patient care. In terms of access, I think another aspect is having integrated workflows. So, being able to schedule patients efficiently, effectively, where more difficult patients automatically get one-hour appointments, patients who have fewer medical difficulties might get shorter appointments. That's another big improvement. Then finally, in terms of physician burnout, having ambient intelligence where notes can be written on your behalf and you just need to double-check them after allows you to really have a much better relationship with the patients. You can actually talk with them one on one and just focus on kind of the holistic care of the patient. And I think that's- being less of a cog in the machine and focusing on your role as a healer would be actually very helpful with the implementation of some of these AI tools. Dr Grouse: You mentioned ambient technology and specifically ambient documentation. And certainly, this is an area that I feel a lot of excitement about from many physicians, a lot of anticipation to be able to have access to this technology. And you mentioned already some of the potential benefits. What are some of the potential… the big wins, but then also potential drawbacks of ambient documentation? Dr Hadar: Just to kind of summarize, the ambient intelligence idea is using kind of an environmental AI system that, without being very obtrusive, just is able to record, able to detect language and process it, usually into notes. So, effectively like an AI scribe that is not actually in the appointment. So, the clear one is that---and I've seen this as well in my practice---it's very difficult to really engage with the patient and truly listen to what they're saying and form that relationship when you're behind a computer and behind a desk. And having that one-on-one interaction where you just focus on the patient, learn everything, and basically someone else takes notes for you is a very helpful component of it. Some of the drawbacks, though, some of it has to do with the existing technology. It's still not at the stage where it can do everything. It can have errors in writing down the medication, writing down the exact doses. It can't really, at this point, detect some of the apprehensions and some of the nonverbal cues that patients and providers may kind of state. Then there's also the big one where a lot of these are still done by startups and other companies where privacy may be an issue, and a lot of patients may feel very uncomfortable with having ambient intelligence tools introduced into their clinical visit, having a machine basically come between the doctor and the patient. But I think that over time these apprehensions will lessen. A lot of the security will improve and be strengthened, and I think that it's going to be incorporated a lot more into clinical practice. Dr Grouse: Yeah, well, we'll all be really excited to see how that technology develops. It certainly seems like it has a lot of promise. You mentioned in your article a lot about how AI can be used to improve screening for patients for certain types of conditions, and that certainly seems like an obvious win. But as I was reading the article, I couldn't help but worry that, at least in the short term, these tools could translate into more work for busy neurologists and more demand for access, which is, you know, already, you know, big problems in our field. How can tools like these, such as, like, for instance, the AI fundoscopic screening for vascular cognitive risk factors help without adding to these existing burdens? Dr Hadar: It's a very good point. And I think it's one of the central points of why we wanted to write the article is that these AI in medicine, it's, it's a tool like any other. And just like when the electronic medical record came into being, a lot of folks thought that this was going to save a lot of time. And you know, some people would say that it actually worsened things in a way. And when you use these diagnostic screening tools, there is an improvement in efficiency, there is an improvement in patient care. But it's important that doctors, patients advocate for this to be value-based and not revenue-based, necessarily. And it doesn't mean that suddenly the appointments are shorter, that now physicians have to see twice as many patients and then patients just have less of a relationship with their provider. So, it's important to just be able to integrate these tools in an appropriate way in which the provider and the patient both benefit. Dr Grouse: You mentioned earlier about the digital twin. Certainly, in your article you mentioned, you know, that idea along with the idea of the potential of development of virtual chatbot visits or in-person visits with a robot neurologist. And I read all this with equal parts, I think excitement, but horror and and fear. Can you tell us more about what these concepts are, and how far are we from seeing technology like this in our clinics, and maybe even, what are the risks we need to be thinking about with these? Dr Hadar: Yeah. So, I mean, I definitely think that we will see implementation of some of these tools in our lifetime. I'm not sure if we're going to have a full walking, talking robot doing some of the clinical visits. But I do think that, especially as we start doing a lot more virtual visits, it is very easy to imagine that there will be some sort of video AI doctor that can serve as, effectively, a digital twin of me or someone else, that can see patients and diagnose them. The idea behind the digital twin is that it's kind of like an AI version of yourself. So, while you only see one patient, an AI twin can go and see two or three other patients. They could also, if the patients send you messages, can respond to those messages in a way that you would, based on your training and that sort of thing. So, it allows for the ability to be in multiple places at once. One of the risks of this is, I guess, overreliance on the technology, where if you just say, we're just going to have a chatbot do everything for us and then not look at the results, you really run the risk of the chatbot just recommending really bad things. And there is training to be had. Maybe in fifty years the chatbot will be at the same level as a physician, but there's still a lot of room for improvement. I personally, I think that my suspicion as to where things will go are for very simple visits in the future and in our lifetime. If someone is having a cold or something like that and it goes to their primary care physician, a chatbot or something like that may be of really beneficial use. And it'll help segment out the different groups of simple diagnosis, simple treatments can be seen by these robots, these AI, these machine learning tools; and some of the more complex ones, at least for the early implementation of this will be seen by more specialized providers like neurologists and subspecialist neurologists too. Dr Grouse: That certainly seems reasonable, and it does seem that the more simple algorithmic things are always where these technologies will start, but it'll be interesting to see where things can go with more complex areas. Now I wanted to switch gears a little bit in the article- and I thought this was really important because I see it as being certainly one of the bigger drawbacks of AI, is that despite the many benefits of artificial intelligence, AI can unfortunately perpetuate systemic bias. And I'm wondering if you could tell us a little bit more about how this happened? Dr Hadar: I know I'm beating a dead horse on this, but AI is a tool like any other. And the problem with it is that what you put in is very similar to what you get out. And there's this idea in computer science of “garbage in, garbage out”. If you include a lot of data that has a lot of systemic biases already in the data, you're going to get results that perpetuate these things. So, for instance, if in dermatologic practices, if you just had a data set that included people of one skin color or one race and you attempted to train a model that would be able to detect skin cancer lesions, that model may not be easily applicable to people of other races, other ethnicities, other skin colors. And that can be very damaging for care. And it can actually really, really hurt the treatments for a lot of the patients. So that is one of the, kind of, main components of the systemic biases in AI. The way we mitigate them is by being aware of it and actually implementing, I guess, really hard stops on a lot of these tools before they get into practice. Being sure, did your data set include this breakdown of sex and gender, of race and ethnicity? So that the stuff you have in the AI tool is not just a very narrow, focused application, but can be generalized to a large population, not just of one community, one ethnic group, racial group, one country, but can really be generalized throughout the world for many patients. Dr Grouse: The first step is being aware of it, and hopefully these models will be built thoughtfully to help mitigate this as much as possible. I wanted to ask as well, another concern about AI is the safety of private data. And I'm wondering, as we're starting to do things like use ambient documentation, AI scribe, and other types of technologies like this, what can we tell our patients who are concerned about the safety of their personal data collected via these programs, particularly when they're being stored or used with outside companies that aren't even in our own electronic medical records system? Dr Hadar: Yeah, it's a very good question, and I think it's one of the major limitations of the current implementation of AI into clinical practice, because we still don't really have great standards---medical standards, at least---for storing this data, how to analyze this data. And my suspicion is that at some point in the future, we're going to need to have a HIPAA compliance that's going to be updated for the 21st century, that will incorporate the appropriate use of these tools, the appropriate use of these data storage, of data storage beyond just PHI. Because there's a lot more that goes into it. I would say that the important thing for how to implement this, and for patients to be aware of, is being very clear and very open with informed consent. If you're using a company that isn't really transparent about their data security and their data sharing practices, that needs to be clearly stated to the patient. If their data is going to be shared with other people, reanalyzed in a different way, many patients will potentially consider not participating in an AI implementation in clinic. And I think the other key thing is that this should be, at least initially, an opt-in approach as opposed to an opt-out approach. So patients really have- can really decide and have an informed opinion about whether or not they want to participate in the AI implementation in medicine. Dr Grouse: Well, thank you so much for explaining that. And it does certainly sound like there's a lot of development that's going to happen in that space as we are learning more about this and the use of it becomes more prevalent. Now, I also wanted to ask, another good point that you made in your article---and I don't think comes up enough in this area, but likely will as we're using it more---AI has a cost, and some of that cost is just the high amount of data and computational processing needed to use it, as well as the effects on the environment from all this energy usage. Given this drawback of AI, how can we think about potential costs versus the benefits, the more widespread use of this technology? Or how should we be thinking about it? Dr Hadar: It's part of a balance of the costs and benefits, effectively, is that AI---and just to kind of name some of them, when you have these larger data centers that are storing all this data, it requires a lot of energy consumption. It requires actually a lot of water to cool these things because they get really hot. So, these are some of the key environmental factors. And at this point, it's not as extreme as it could be, but you can imagine, as the world transitions towards an AI future, these data centers will become huge, massive, require a lot of energy. And as long as we still use a lot of nonrenewable resources to power our world, our civilization, I think this is going to be very difficult. It's going to allow for more carbon in the atmosphere, potentially more climate change. So, being very clear about using sustainable practices for AI usage, whether it be having data centers specifically use renewable resources, have clear water management guidelines, that sort of thing will allow for AI to grow, but in a sustainable way that doesn't damage our planet. In terms of the financial costs… so, AI is not free. However, on a given computer, if you want to run some basic AI analysis, you can definitely do it on any laptop you have and sometimes even on your phone. But for some of these larger models, kind of the ones that we're talking about in the medical field, it really requires a lot of computational power. And this stuff can be very expensive and can get very expensive very quickly, as anyone who's used any of these web service providers can attest to. So, it's very important to be clear-eyed about problems with implementation because some of these costs can be very prohibitive. You can run thousands and you can quickly rack up a lot of money for some very basic analysis if you want to do it in a very rapid way, in a very effective way. Dr Grouse: That's a great overview. You know, something that I think we're all going to be having to think about a lot more as we're incorporating these technologies. So, important conversations I hope we're all having, and in our institutions as we're making these decisions. I wanted to ask, certainly, as some of our listeners who may be still in the training process are hearing you talk about this and are really excited about AI and implementation of technology in medicine, what would you recommend to people who want to pursue a career in this area as you have done? Dr Hadar: So, I think one of the important things for trainees to understand are, there are different ways that they can incorporate AI into their lives going forward as they become more seasoned doctors. There are clinical ways, there are research ways, there are educational ways. A lot of the research ways, I'm one of the researchers, you can definitely incorporate AI. You can learn online. You can learn through books about how to use machine learning tools to do your analysis, and it can be very helpful. But I think one of the things that is lacking is a clinician who can traverse both the AI and patient care fields and be able to introduce AI in a very effective way that really provides value to the patients and improves the care of patients. So that means if a hospital system that a trainee is eventually part of wants to implement ambient technology, it's important for physicians to understand the risks, the benefits, how they may need to adapt to this. And to really advocate and say, just because we have this ambient technology doesn't mean now we see fifty different patients, and then you're stuck with the same issue of a worse patient-provider relationship. One of the reasons I got into medicine was to have that patient-provider interaction to not only be kind of a cog in the hospital machine, but to really take on a role as a healer and a physician. And one of the benefits of these AI tools is that in putting the machine in medicine, you can also put the humanity back in medicine at times. And I think that's a key component that trainees need to take to heart. Dr Grouse: I really appreciate you going into that, and sounds like there's certainly need. Hoping some of our listeners today will consider careers in pursuing AI and other types of technologies in medicine. I really appreciate you coming to talk with us today. I think this is just such a fascinating topic and an area that everybody's really excited about, and hoping that we'll be seeing more of this in our lives and hopefully improving our clinical practice. Thank you so much for talking to us about your article on AI in clinical neurology. It was a fascinating topic and I learned a lot. Dr Hadar: Thank you very much. I really appreciate the conversation, and I hope that trainees, physicians, and others will gain a lot and really help our patients through this. Dr Grouse: So again, today I've been interviewing Dr Peter Hadar about his article on clinical applications of artificial intelligence in neurology practice, which he wrote with Dr Lydia Moura. This article appears in the most recent issue of Continuum on neuro-ophthalmology. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. Thank you for listening to Continuum Audio.

This Episode is dedicated to the memory and honor of the service of Dan Allen and Dominic Snyder.Special Thank You to the Liverpool Football Club and the Royal British Legion for hosting these families."Thank you to the amazing organizations of TAPS, SSAFA, and Home Base for bringing together healed hearts and healed families." - Dustin Snyder.The 2nd Annual Run To Anfield is coming up – AUGUST 2nd, 2025 – So come join us or Run/Walk or support with us virtually anywhere in the world. Especially if you are a Liverpool fan of course.Go to: www.liverpoolfc.com/foundation/run-anfield ______________Run To Home Base: Join Ron and his team and sign up individually or on another team at the 16th annual Run To Home Base on July 26th, 2025, at Fenway Park! Go to runtohomebase.orgPlease go to homebase.org for updates, programming, and resources if you or anyone you know is struggling. Home Base Nation is the official podcast for the Home Base Program for Veterans and Military Families. Our team sees veterans, service members, and their families addressing the invisible wounds of war at no cost. This is all made possible thanks to a grateful nation. If you want to learn more about how to help, visit us at www.homebase.org. If you or anyone you know would like to connect to care, you can also reach us at 617-724-5202.Follow Home Base on Twitter, Facebook, Instagram, LinkedInThe Home Base Nation Team is Steve Monaco, Army Veteran Kelly Field, Justin Scheinert, Chuck Clough, with COO Michael Allard, Brigadier General Jack Hammond, and Peter Smyth.Producer and Host: Dr. Ron HirschbergAssistant Producer, Editor: Chuck CloughChairman, Home Base Media Lab: Peter SmythThe views expressed by guests on the Home Base Nation podcast are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent. Views and opinions expressed by guests are those of the guests and do not necessarily reflect the views of the Massachusetts General Hospital, Home Base, the Red Sox Foundation, or any of its officials.

"It's really just an extension of the general ethos in medicine which has existed for a very long time – generations, centuries - which says that in order to make other people well we have to make ourselves sick. That is only recently being questioned. "This episode is with Dr. Suzanne Koven who was a primary care physician at Massachusetts General Hospital for over 30 years, has had a prolific literaray career and now serves as the Writer in Residence of Massachusetts General Hospital full time.In this episode we talk about:- Her experience having a baby in residency - Pre-eclampsia- Being asked to write her own maternity leave policy - Her feelings about going part time and what her primary care patients thought about this- What it was like to retire from clinical medicine (spoiler alert - she doesn't miss it)- How she got started in her literary career- The importance of sharing stories- Her book Letter to a Young Female Physician and how that came about- The memoir that she is currently writing Connect with Moms of Medicine:- Instagram @moms_of_medicine- Momsofmedicine@gmail.comConnect with Dr. Suzanne Koven:- Instagram @kovensuzanne

We have published 120 episodes since 2019. For this new season, we thought we would look back on some of the highlights of our conversations and choose 20 episodes that resonated with veterans, service members, military families, and the civilians who support them.But first up, you'll hear from some of the folks at Home Base who wake up every day with the same mission in mind, no matter what they do at the Center of Excellence in the Navy Yard and beyond.Over the next twenty weeks, we will share these staff conversations I had with some of the hard-working professionals at Home Base who help treat the invisible wounds of veterans and military families.For this episode, you will hear a brief conversation with Clinical Social Worker Kate Basile, who works in the Intensive Clinical Program at Home Base. This will be followed by our very first episode, in which we sat with journalist, author, and filmmaker Sebastian Junger.Many thanks to Kate Basile for all her work at Home Base in support of this mission to stomp stigma and treat the invisible wounds of veterans and military families.Run To Home Base: Join Ron and his team and sign up individually or on another team at the 16th annual Run To Home Base on July 26th, 2025, at Fenway Park! Go to runtohomebase.orgPlease go to homebase.org for updates, programming, and resources if you or anyone you know is struggling. Home Base Nation is the official podcast for the Home Base Program for Veterans and Military Families. Our team sees veterans, service members, and their families addressing the invisible wounds of war at no cost. This is all made possible thanks to a grateful nation. If you want to learn more about how to help, visit us at www.homebase.org. If you or anyone you know would like to connect to care, you can also reach us at 617-724-5202.Follow Home Base on Twitter, Facebook, Instagram, LinkedInThe Home Base Nation Team is Steve Monaco, Army Veteran Kelly Field, Justin Scheinert, Chuck Clough, with COO Michael Allard, Brigadier General Jack Hammond, and Peter Smyth.Producer and Host: Dr. Ron HirschbergAssistant Producer, Editor: Chuck CloughChairman, Home Base Media Lab: Peter SmythThe views expressed by guests on the Home Base Nation podcast are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent. Views and opinions expressed by guests are those of the guests and do not necessarily reflect the views of the Massachusetts General Hospital, Home Base, the Red Sox Foundation, or any of its officials.

Dr. Jennifer Wargo is an Associate Professor in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center and a Stand Up To Cancer researcher. Jennifer is a physician scientist, and this means she splits her time between providing care to patients and doing research to find better ways of treating disease. Specifically, Jennifer performs surgeries and treats patients one day each week. She spends the rest of her week studying how to better treat patients with cancer and how cancer may ultimately be prevented. When she's not doing research or treating patients, Jennifer enjoys spending quality time with her family. Some of their favorite activities include going for walks, biking, hiking, and visiting the beach. Jennifer also likes to explore her creative side through art and photography, as well as to be active through running, biking, yoga, and surfing. She received her A.S. degree in nursing and B.S. degree in biology from Gwynedd-Mercy College. Afterwards, Jennifer attended the Medical College of Pennsylvania where she earned her M.D. Jennifer completed her Clinical Internship and Residency in General Surgery at Massachusetts General Hospital. Next, Jennifer was a Research Fellow in Surgical Oncology at the University of California, Los Angeles. She then accepted a Clinical Residency in General Surgery at Massachusetts General Hospital. From 2006-2008, Jennifer was a Clinical Fellow in Surgical Oncology at the National Cancer Institute of the National Institutes of Health. She then served on the faculty at Massachusetts General Hospital and Harvard University. In 2012, Jennifer received her MMSc. degree in Medical Science from Harvard University. Jennifer joined the faculty at The University of Texas MD Anderson Cancer Center in 2013. She is Board Certified by the American Board of Surgery, and she has received numerous awards and honors throughout her career. These have included the R. Lee Clark Prize and Best Boss Award from the MD Anderson Cancer Center, the Rising STARS and The Regents' Health Research Scholars Awards from the University of Texas System, the Outstanding Young Investigator and Outstanding Investigator Awards from the Society for Melanoma Research, as well as a Stand Up To Cancer Innovative Research Grant for her microbiome work. She has also received other awards for excellence in teaching, research, and patient care. In our interview, Jennifer shares more about her life and science.

John's monologue first discusses Jake Tapper's new book "Original Sin" which blames White House staffers and the media for covering up President Biden's supposed cognitive decline. He also talks about Trump in Saudi Arabia, where he met with Arab business leaders, hoping to land the next great freebie. He also announced an imminent cessation of sanctions on Syria, a major policy shift encouraged by both Saudi Arabia and Turkey. Then, Professor Corey Brettschneider returns to debate about Supreme Court Justice John Roberts' weak Trump rebuke, whether a president can suspend habeas corpus, and birthright citizenship which is now heading to the Supreme Court. Next, John interviews Dr. Anahita Dua - who is an Assistant Professor at Harvard Medical School and a vascular surgeon at the Massachusetts General Hospital. They talk about Trump's choice for Surgeon General: Right-Wing wellness Influencer Casey Means. And then finally, comedian Keith Price is back to joke with listeners about the latest trends and the firehose of dumpster fire news coming from the GOP and "Man-Baby".See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We have published 120 episodes since 2019. For this new season, we thought we would look back on some of the highlights of our conversations and choose 20 episodes that resonated with veterans, service members, military families, and the civilians who support them.But first up, you'll hear from some of the folks at Home Base who wake up every day with the same mission in mind, no matter what they do at the Center of Excellence in the Navy Yard and beyond.Over the next twenty weeks, we will share these staff conversations I had with some of the hard-working professionals at Home Base who help treat the invisible wounds of veterans and military families.For this episode, you will hear a brief conversation with Home Base Marine Veteran Alexander Hohl, Licensed Mental Health Counselor, followed by one of the earlier episodes, in which Ron sat with the US Army Colonel and Combat Surgeon Dr. David King and Red Sox legend David "Big Papi" Ortiz.  Boston just celebrated the 250th anniversary of the American Revolution, and we felt it a good time to re-share the episode that remembers the Boston Marathon bombing and the inspiration Big Papi brought to the city during that time.Many thanks to Alexander Hohl for all his work at Home Base to support this mission to stomp stigma and treat the invisible wounds of veterans and military families.Run To Home Base: Join Ron and his team and sign up individually or on another team at the 16th annual Run To Home Base on July 26th, 2025, at Fenway Park! Go to runtohomebase.orgPlease go to homebase.org for updates, programming, and resources if you or anyone you know is struggling. Home Base Nation is the official podcast for the Home Base Program for Veterans and Military Families. Our team sees veterans, service members, and their families addressing the invisible wounds of war at no cost. This is all made possible thanks to a grateful nation. If you want to learn more about how you can help, visit us at www.homebase.org. If you or anyone you know would like to connect to care, you can also reach us at 617-724-5202.Follow Home Base on Twitter, Facebook, Instagram, LinkedInThe Home Base Nation Team is Steve Monaco, Army Veteran Kelly Field, Justin Scheinert, Chuck Clough, with COO Michael Allard, Brigadier General Jack Hammond, and Peter Smyth.Producer and Host: Dr. Ron HirschbergAssistant Producer, Editor: Chuck CloughChairman, Home Base Media Lab: Peter SmythThe views expressed by guests on the Home Base Nation podcast are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent. Views and opinions expressed by guests are those of the guests and do not necessarily reflect the views of the Massachusetts General Hospital, Home Base, the Red Sox Foundation, or any of its officials.

We just celebrated Mother's Day, which may not have been what you expected. It can be a complicated day when people don't show up or recognize you as you deserve. I want to acknowledge the complex feelings that come with Mother's Day and say that you aren't alone in experiencing those emotions. Whatever your Mother's Day brought you, I hope you feel recognized and supported. Today, we are bringing you another great episode during Maternal Mental Health Month as we uncover the purpose of a new podcast filling a gap for many people. Join us to learn more about this vital resource! Allie Hales, a mom of four, is passionate about making reliable, relevant information available for moms like herself. She graduated from the J. Reuben Clark Law School at Brigham Young University and is a member of the Massachusetts Bar. She serves on Brigham and Women's Hospital's Newborn Medicine and Reproductive Health Advisory Board, Newton-Wellesley Hospital's Maternal Services Council, and is actively involved with the Boston Center for Endometriosis. Allie grew up in the suburbs of Boston and currently lives in Baltimore with her four children and her husband, Riley, a resident in anesthesia at Johns Hopkins Hospital.  Dr. Ruta Nonacs completed a perinatal and reproductive psychiatry fellowship at Massachusetts General Hospital. She is a clinical instructor at Harvard Medical School, a senior psychiatrist with the Center for Women's Mental Health at Massachusetts General Hospital, and the creator and editor-in-chief of their website,⁠ ⁠⁠womensmentalhealth.org⁠. She, with Allie Hales, co-hosts the new podcast,⁠ So Glad You Asked⁠. Dr. Ruta's work has been published in numerous scientific journals and books, and she is the author of⁠ A Deeper Shade of Blue: A Woman's Guide to Recognizing and Treating Depression in Her Childbearing Years. ⁠ Show Highlights: Highlights of Dr. Ruta's path to her current work Allie's lived experience in her mental health journey and her connection to Dr. Ruta Barriers to getting information and accessing treatment The importance of lived experience in developing solutions and strategies Moms, questions, and a new podcast Giving a voice to “regular moms” and providing evidence-based solutions Major topics planned for upcoming podcast episodes (Dr. Ruta and Allie have a huge list!) The connection between the podcast and a resource hub at ⁠womensmentalhealth.org⁠ Accessible information IS preventative. The podcast schedule and plans for the first season Dr. Ruta and Allie's hopes and dreams for their podcast to empower and support women Resources: Connect with Dr. Ruta Nonacs and Allie Hales:⁠ Women's Mental Health website⁠,⁠ Instagram⁠,⁠ So Glad You Asked⁠ podcast, and⁠ A Deeper Shade of Blue: A Woman's Guide to Recognizing and Treating Depression in Her Childbearing Years⁠. Call the National Maternal Mental Health Hotline at 1-833-TLC-MAMA or visit⁠ cdph.ca.gov⁠ Please find resources in English and Spanish at⁠ Postpartum Support International⁠, or by phone/text at 1-800-944-4773. There are many free resources, like online support groups, peer mentors, a specialist provider directory, and perinatal mental health training for therapists, physicians, nurses, doulas, and anyone who wants to be more supportive in offering services.  You can also follow PSI on social media:⁠ Instagram⁠,⁠ Facebook⁠, and most other platforms Visit⁠ www.postpartum.net/professionals/certificate-trainings/⁠ for information on the grief course.   Visit my website,⁠ www.wellmindperinatal.com⁠, for more information, resources, and courses you can take today! If you are a California resident looking for a therapist in perinatal mental health, ⁠email me⁠ about openings for private pay clients! Learn more about your ad choices. Visit podcastchoices.com/adchoices

Dr. Robert Waldinger talks about his new book The Good Life: Lessons From the World's Longest Scientific Study of Happiness, which explores lessons from the longest scientific study of happiness. Dr. Robert Waldinger is a professor of psychiatry at Harvard Medical School, the director of the Harvard Study of Adult Development at Massachusetts General Hospital, and co-founder of the Lifespan Research Foundation. He is also a Zen master and teaches meditation in New England and around the world. His TED Talk is one of the most viewed of all time, with over 43 million views. He's the co-author, along with Dr. Marc Schulz, of The Good Life.   In this episode we talk about:  What the Harvard Study of Adult Development is and how it got started How much of our happiness is really under our control Why you can't you be happy all the time The concept of “social fitness”  Why you should “never worry alone”  How having best friends at work can make you more productive And why, in his words, it's never too late to be happy   Join Dan's online community here Follow Dan on social: Instagram, TikTok Subscribe to our YouTube Channel